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ABSTRACT
Proteoglycans (PGs), a special class of gly coconjugates, which decorate the 
outer surface of mammalian cells, consist of a core protein and several 
glycosaminoglycan (GAG) side chains. PGs regulate many important biological 
processes, such as fertilization, cell-cell communication, immune defense, 
anticoagulation, angiogenesis, axon guidance, and many more. Controlling the fine 
structures of endogenous GAG chains or modulating expression levels of GAG chains 
can significantly impact many biological processes. However, very little is known 
about the factors that regulate PG biosynthesis. In this thesis work, chemical probes 
were designed and synthesized to understand biosynthetic pathways, structures, and 
functions of PGs. A library of xylosides with different aglycone groups was 
synthesized using “click chemistry” to stimulate and inhibit GAG production in vitro. 
These molecular probes serve as excellent tools to unravel the biological significance of 
PGs and GAG multivalency in many biological systems and lead to the discovery of 
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1.1.1. Structures of Proteoglycans
Proteoglycans (PGs) are the most ubiquitous gly coconjugates found on cell 
surfaces and in the extracellular matrix (ECM) (1-8). PG consists of a core protein and 
two or more glycosaminoglycan (GAG) chains with the exception of decorin (1-8). 
Four major classes of sulfated GAG chains are heparan sulfate (HS), chondroitin sulfate 
(CS), dermatan sulfate (DS), and keratan sulfate (KS) (1-8). GAG chains, with the 
exception of KS, are linked to a serine residue of the core proteins by O-glycosylation 
via a specific tetrasaccharide linker, “Xyl-Gal-Gal-GlcA” (1-8). The differences among 
HS, CS, and DS are in their constituent repeating disaccharide units. HS consists of 
glucosamine and glucuronic (GlcA)/iduronic (IdoA) acid, CS consists of galactosamine 
and GlcA, and DS is composed of galactosamine and GlcA/IdoA (Figure 1.1) (1-8). In 
addition to having differing disaccharide compositions and chain length, GAGs display 
structural variation through sulfation of hydroxyl groups (8 ). Since GAGs have a large 
number of potential sulfate sites and different combinations of sulfated disaccharides, 
the sulfate patterns of GAG are diverse (8 ). For example, HS disaccharide unites can be 
sulfated at C-2 of hexoronic acid or at C-3 and C- 6  positions of glucosamine. C-2 
amine of glucosamine can be acetylated, sulfated, or unmodified. CS disaccharides 
unites can be sulfated at the C-4 and C- 6  of galactosamine as well as C-2 of uronic acid 
(8 ). Moreover, the structural diversity is also obtained by conformational flexibility of 
the pyranose ring of IdoA, which exists in equilibrium between the chair and skew-boat 
conformations (9). In conclusion, the combination of different sequences, charge
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3Figure 1.1. Structure of proteoglycans
distribution, and conformations give structural diversity within GAG chains that 
regulate many important and specific biological functions.
1.1.2. Functions of Proteoglycans
PGs regulate many biological/pathological processes by binding to various 
proteins, such as growth factors, morphogens, antithrombin, and viral proteins. The list 
of normal and pathological processes is as follows: development, cell-cell 
communication, immune defense, viral and parasitic infections, anticoagulation, 
angiogenesis, tumor metastasis, organogenesis, morphogenesis, axon guidance, growth, 
and many more (Figure 1.2) (1, 2, 8, 10-15).
Recombinant heparinase I and heparinase III from Pedobacter heparinus 
depolymerize HS in a mouse model into HS fragments, which either promote or inhibit 
tumor (16). Chondroitinase ABC, which degrades CS, promotes functional recovery 
following central nervous system injury in adult rats (17). The biological functions of
B: Cell-Cell crosstalk
C: Maintain morphogen gradients across cell surface
F: Coagulation E: Invasion
Figure 1.2. Functions of proteoglycans in cell physiology
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PGs depend on the interactions between specific sulfate groups and cationic amino acids 
of protein ligands (1, 2, 10-14, 18, 19). For example, 2-O-sulfate groups are important 
for the kidney development, whereas 6 -O-sulfate groups of HS are necessary for the 
fibroblast growth-driven formation of the tracheal system in Drosophila (20). The 
pentasaccharide subunit of heparin with 3-O-sulfate groups is required for binding to 
antithrombin III and producing a 1000-fold increase in antithrombin III’s ability to 
neutralize thrombin. The heparin-antithrombin III complex also inhibits thrombin 
production by inactivating factor Xa (18, 20, 21).
Another prominent example of the importance of GAG chains in pathology is that 
of HS in cancers (1-3, 19). Dramatic changes in the expression of biosynthetic and 
catabolic enzymes are attributed to alterations in HS structures, which are suggested to 
affect tumor cell growth, invasion, and metastasis (1-3). For example, heparanase, a P- 
endoglucuronidase, which is over-expressed in malignant tumors, cleaves HS chains into 
smaller biologically active oligosaccharides that promote cancer growth, angiogenesis, 
tumor-cell invasion, and migration (22-24).
Even though PGs play a fundamental role in many biological processes, a 
molecular level understanding of the roles of specific number of chains, average 
molecular weight, and sulfate patterns in mediating their functions is largely unknown 
(8 ). PGs purified from natural sources are mixtures of chains that contain different 
sulfate patterns and chain lengths (8 ). Current clinical data and in vitro studies suggest 
that several GAG chains and their derivatives can be used as therapeutics in 
antithrombolysis (21, 25-27). However, direct administration of these animal-derived 
GAG chains faces the problem of molecular heterogeneity, possible contamination with
5
6pathogens, or intentional chemical adulteration (28). Therefore, the synthesis of PGs 
containing defined number of chains, average molecular weight, sulfate patterns, and 
HS/CS compositions has the potential to advance our understanding of the structure- 
activity relationships of PGs and the use of PG inducers as therapeutic agents. In this 
thesis, a chemical approach using xylosides was designed and induced GAG chain 
biosynthesis without a core protein. The xyloside technology can control the molecular 
weight, sulfate pattern, and GAG composition by introducing and changing the 
hydrophobic aglycone group next to the xylose unit. Therefore, these xylosides can 
decipher the roles of PGs in biological process accurately. Moreover, the xyloside 
technology will have potential to be used as therapeutics to ameliorate a variety of 
disease states.
1.1.3. The Roles of RGD Peptides in Targeting Specific Cells and 
Antiplatelet Aggregation Therapy
The thrombotic process involves the aggregation of platelets, which is mediated 
by fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor on the surface of 
activated platelets (29). Inhibition of fibrinogen binding to the GP IIb/IIIa has been 
demonstrated to inhibit platelet aggregation (29). Several GP IIb/IIIa inhibitors have a 
tripeptide sequence, RGD, which is responsible for the recognition of fibrinogen by the 
GPIIb/IIIa (29). Therefore, RGD derivative can bind to GP IIb/IIIa receptor instead of 
fibrinogen in order to inhibit platelet aggregation (29). Moreover, RGD selectively binds 
to avp3 integrins that are abundantly expressed on the surface of activated endothelial 
cells and cancers (30).
7Linear and cyclic RGD peptides have been employed as targeting vehicles for 
selective delivery of therapeutic and diagnostic agents (30). Therefore, conjugating RGD 
peptides to xylose residues leads to the development of anticoagulant or anticancer drugs 
because they can selectively target activated endothelial cells, which can induce 
therapeutic GAGs at a local site, and can bind to GP IIb/IIIa receptor to inhibit the 
platelet aggregation.
1.1.4. Biosynthesis of GAG Chains
The biosynthesis of GAG chains involves many enzymes with many isoforms as 
well as sugar activators (31, 32). The specific structures of GAG chains are synthesized 
in specific compartments that contain a specific enzyme in the Golgi apparatus called 
GAGOSOMEs (18, 33). The biosynthesis of GAG chains involves three stages: 
tetrasaccharide linkage region assembly, GAG chain elongation, and GAG chain 
modification (18, 31, 32). The tetrasaccharide linkage is assembled to initiate the GAG 
chains, followed by GAG chain elongation. When the chain polymerizes, it undergoes a 
series of modifications (18, 31, 32). However, the expression level of enzymes affects 
both polymerization and type/extent of modifications (34). For example, exostosin 
proteins (EXT1 and EXT2) affect the action of #-deacetylase #-sulfotranserase 1 (NDST 
1), which influences further modification (34).
1.1.4.1. Assembly o f GAG linkage region
The biosynthesis of GAG chains is initiated by the transfer of xylose (Xyl) 
residue from the UDP-Xyl to certain serine amino acids in the core proteins by
xylosyltransferase in the endoplasmic reticulum (18, 31, 32, 35). Next, two galactose 
(Gal) residues are transferred by galactosyltransferases I and II (18, 31, 32). Subcellular 
fractionation of chick cartilage demonstrated that two Gal transferases reside in different 
parts of the cis/medial Golgi (18, 31, 32). The attachment of one GlcA residue by 
glucuronosyltransferase completes the formation of the tetrasaccharide linkage region 
(18, 31, 32). The linkage region undergoes a series of additional modifications such as 
sulfation/sulfonation and phosphorylation (18). 2-O-Phosphorylation of Xyl and 6 -O- 
sulfation of Gal affect the activity of glucuronyltransferase-I in order to complete the 
tetrasaccharide linkage (36). The linkage region in a variety of CS and DS contains 4-O 
or 6 -O-sulfated Gal residues, but the linkage region of HS does not (18, 31). No specific 
Gal sulfotransferases have been found for the linkage region, which suggests that sulfate 
of both Gal residues are catalyzed by the same sulfotransferases that add sulfate groups to 
the disaccharides of CS (31). A sequence of core protein amino acids contributes to the 
specification of CS/DS or HS (31, 37). In general, Ser-Gly sites are necessary to 
facilitate the xylose transfer. Amino acid sequences of CS attachment sites have the 
following consensus sequence: a-a-a-a-Gly-Ser-Gly-a-b-a (where a = Glu or Asp and b= 
Gly, Glu or Asp) (31).
1.1.4.2. GA G elongation and modification
The pathways of HS and CS/DS synthesis are different after the formation of the 
linkage region. The addition of a-4-#-acetyl glucosamine (GlcNAc) to the linkage 
region is required for the assembly of HS, whereas the addition of P-4-#-acetyl 
galactosamine (GalNAc) is necessary for CS/DS chains (31, 32, 38). The GlcNAc
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transferase has a domain that interacts with the acidic residues either near the core protein 
or one or more hydrophobic residues of exogenous xylosides; this then facilitates 
selective addition of a-4-GlcNAc to trigger HS assemblies (32, 38). After the attachment 
of the first a-GlcNAc residue, HS chains are formed by repetitive addition of GlcA and 
GlcNAc units by enzymes EXT1 and EXT2 (18, 32). For CS biosynthesis, upon 
completion of the linkage region and the addition of the first GalNAc, the polymerization 
of CS chains continues with the repetitive addition of GlcA and GalNAc residues using 
CS synthase (31). Density gradient subfractionation have indicated that the polymer 
formation in CS happens in medial/trans Golgi (31).
While elongation is in progress, parts of the GAG chains are modified via highly 
coordinated multiple sulfation/epimerization steps (18). For HS biosynthesis, one of the 
important modifications is #-deacylation and ^-sulfation of GlcNAc residues (32). The 
#-acetyl groups from GlcNAc units are removed to generate positively charged free 
amino groups, which are then substituted with sulfate groups using 3' -phosphoadenosine 
5'-phosphosulfate (PAPS) as sulfate donor by a bifunctional enzyme (NDST) (18, 32). L- 
IdoA residues are formed by epimerization of D-GlcA next to the reducing side of GlcNS 
units using C5-epimerase (18, 32). The latter modifications are facilitated by a variety of 
O-sulfotransferases (OST), which transfer the sulfate groups from PAPS to the HS chains 
at specific locations such as the C-2 position of IdoA (2-OST), and to the C-3 and C- 6  
position of Glc residues (3-OST and 6 -OST) (Figure 1.3) (18, 32). For CS sulfate, 4- 
OST and 6 -OST enzymes transfer sulfate groups from PAPS to C-4 and C- 6  of GalNAc 
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Figure 1.3. Biosynthesis of glycosaminoglycans
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case of DS, 4-OST and 6 -OST transfer sulfate groups from PAPS to C-4 and C- 6  of 
GalNAc residues and 2-OST transfers sulfate groups to C-2 of IdoA residues (31).
1.1.5. Chemical Approaches to Modulate Cellular GAG Biosynthesis
1.1.5.1. Stimulation o f GAG chains
Exogenous xylosides have been used both in vitro and in vivo to probe the 
functional significance of GAG chains in various dynamic systems under different 
conditions (39-51). The story began with D-xylose, which acted as an initiator of CS 
biosynthesis in progeny of brd U-treated limb bud cells at high concentrations (52). 
Several studies observed that P-D-xylosides, such as ^-nitro-phenyl-P-D-- 
xylopyranoside and 4-methyl-umbellifery-P-D-xylophyranoside, can stimulate protein- 
free CS chains more effectively than D-xylose in various cell types at much lower 
concentrations (50). An interesting observation is that the nature of the aglycone group 
and glycosidic linkages of P-D-xylosides influenced the extent of stimulation of CS 
biosynthesis (47). These molecules containing a hydrophobic aglycone can compete 
with endogenous core protein receptor sites for the assembly of GAG chains in the Golgi 
apparatus (39-43, 45) (46). In addition, the hydrophobic aglycone could help xylosides 
pass through the membrane and therefore increase priming activity/production of GAG 
chains. The glycosidic linkage of P-D-xylosides also affects GAG priming activity (45). 
A library of aryl and alkyl-O-P-D-xylosides and their analogues with S, NH, or CH2 in 
the glycosidic linkage was synthesized and tested for their priming activities (53). S- 
xylosides were more effective primers than the corresponding N-xylosides and C- 
xylosides (53). In addition, the relationship of the structure of the sugars to their priming
11
activity was evaluated by synthesizing P-D-xyloside analogs in which the hydroxyls 
were substituted with -hydrogen, -fluorine, -O-methyl, -amino, -O-isopropyl, -O-benzyl 
groups, and epimers at the 2-, 3-, and 4-position of xylose units (44). The substitution of 
2-OH and 3-OH with -OCH3 of xylose units primed better at a higher concentration 
(1mM) (44). The fluorine derivative at C-3 primed more efficiently than the 3-OH 
group (44). However, methylated and deoxy analogs at C-4 did not prime due to the loss 
of the acceptor hydroxyl group (44).
In most cases, priming of CS dominates and synthesis of core-protein free HS 
chains is low or undetectable (53, 54). Several studies suggested that increased yields of 
HS can be obtained when the aglycones of the xylosides comprise aromatic, polycyclic 
structures such as naphthyl derivatives. 2-(6-hydroxynaphthyl)-P-D-xylopyranoside is 
the first molecules that primed a small amount of HS, which selectively inhibited growth 
of transformed or tumor-derived cells (55, 56). Moreover, the composition of GAG 
chains also depends on the chemical structures of the aglycone groups (56). For 
example, ortho-nitro-phenyl-D-xyloside produced the composition of HS and CS (20- 
and 100-fold) (56). However, para-nitro-phenyl-xyloside produced only 37 and 3-fold 
of CS and HS, respectively (56). Estradiol-P-D-xyloside was also an efficient primer for 
HS biosynthesis and the proportion of HS was raised with increasing concentration of 
this xylosides (57). Earlier studies led to a conclusion that P-D-xyloside carrying two 
aromatic rings efficiently primed HS, and replacing an oxygen atom with a sulfur atom 
also increased the efficiency of HS priming (39). However, these synthetic xylosides are 
very labile. Therefore, it is important to synthesize stable, small molecular xylosides 
that prime both HS and CS at lower dosages to study biological roles.
12
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Several studies describe an additional approach to stimulate the GAG 
biosynthesis by using disaccharides as primers (58). However, Chinese hamster ovary 
cells did not take up these disaccharides efficiently, and the priming activity of 
disaccharides was improved by protecting the hydroxyl groups with acetyl groups (58).
Multiple GAG attachment sites are found in various PGs (5). This implied that 
multiple GAG chains are required for optimal biological functionality of PG in various 
species. Single GAG chains can perhaps not provide the same functionality that 
multiple GAG chains can. Several earlier studies have rigorously utilized synthetic 
mono-xylosides to further our understanding of the role of endogenous PGs in model 
organisms and also to elucidate the elusive biosynthetic mechanism (39-51). Only one 
study has examined synthetic bis-xylosides, which carry two xylose residues per 
molecular scaffold, for their priming activity (48). However, these synthetic bis- 
xylosides carry labile O-glycosidic linkage. Therefore, it is important to synthesize 
stable, small molecular scaffolds carrying a variable number of xylose residues to study 
the importance of multivalency of GAG.
The priming activity of xylosides is often tested using a mutant Chinese hamster 
ovary cell line (pgsA-745) (59). This cell line lacks active xylosyltransferases enzyme; 
therefore, the process requires an exogenous supply of xylosides to produce GAG chains 
(59). These xylosides pass through membranes of cells, stimulate GAG in the Golgi 
apparatus, then secret outside of the membranes (Figure 1.4).
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Figure 1.4. Xylosides prime GAG chains
1.1.5.2. Inhibition o f GAG biosynthesis
No group has developed a selective or effective inhibitor of endogenous GAG 
production. The majority of inhibitors developed lack specificity and cannot be used for 
in vivo studies (60-65). Rhodamine B inhibited GAG production by an unknown 
mechanism, which effectively reduced GAG storage in somatic tissues and brain (60). 
However, the use of rhodamine B in clinical practice is unlikely due to its possible toxic 
effects (61). Brefeldin A (BFA), a fungal isoprenoid metabolite, inhibits the secretary 
transport of Golgi vesicles, an important step in HS and CS biosynthesis (62). However, 
BFA affects the biosynthesis of other glycoconjugates as well (63). Therefore, BFA is 
not an effective inhibitor of endogenous GAG production because it is difficult to use 
BFA to pinpoint the biological actions of GAG chains without affecting other 
glycosylation events (63). To elucidate the biological significance of sulfated groups of 
GAG chains, several approaches have been employed (64, 65). For example, sodium 
chlorate can inhibit the formation of PAPS by competitively binding to PAPS synthase 
and thereby affect GAG sulfation (64, 65). However, since a high concentration of
chlorate is required for it to be effective, chlorate is not suitable for in vivo experiments 
(65). In addition, sodium chlorate unselectively affects all the sulfation patterns (65). In 
another approach, a series of 4-deoxyglucosamine analogs were examined for their 
ability to inhibit GAG biosynthesis in hepatocytes (66). GAG chains isolated from 
analog-treated hepatocytes were shown to be smaller in size than those isolated from 
control cells (66). Unfortunately, these analogs are not selective inhibitors of GAG 
biosynthesis and affect the biosynthesis of other glycoconjugates as well. Therefore, it is 
important to synthesize a library that can selectively inhibit GAG biosynthesis without 
having any toxic effects on cells to identify the biological functions of GAG chains.
1.2. Research Objectives
Overall, my goals are to study structure-function relationship and biosynthesis of 
PGs in vitro by synthesizing carbohydrate-based cellular probes. Controlling the fine 
structures of endogenous and exogenous GAG chains significantly regulates many 
important biological processes. In addition, targeting the exogenous GAG chains to 
activated endothelial cells and cancer cells impacts the growth, invasion, and metastatic 
properties of tumor cells. Therefore, a library of xylosides was synthesized to 
understand biosynthetic pathways, structure, and functions of PGs.
1.2.1. Specific Aim I
A number of xylosides were studied to understand the mechanism of GAG 
biosynthesis. In the first part, the importance of the chemical structures of aglycone 
groups was demonstrated in priming activity and fine structures of primed GAG chains.
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Most of the xylosides that were studied make mostly CS and a very little HS. For 
example, a library of P-O- xylosides was examined to stimulate different amounts of CS 
and DS chains at specific concentrations. However, O-xylosides are considered to be 
hydrolytically unstable in cells. A library of xylosides with different aglycone groups 
was designed using fast reactions “click chemistry” because of its high efficiency, 
regioselectivity, biological compatibility, and chemical stability in aqueous/organic 
solvents. These xylosides were tested in a Chinese hamster ovary cell line (pgsA-745), 
which lacks active xylosyltransferases enzyme. The results show that these xylosides 
are stable for at least five days, and demonstrate the importance of aglycone groups in 
priming activity and induce specific structures of GAGs. In the second part of this 
study, GAG biosynthesis was inhibited using 4-F-xylosides. From the first part, 
xylosides containing a specific hydrophobic aglycone are efficient acceptors for the 
elongation of GAG chains; therefore, the 4-OH group of these xylosides was blocked to 
prevent the galactosyltransferase from transferring galactose to the xylosides and inhibits 
GAG biosynthesis without toxicity to cells at various concentrations.
1.2.2. Specific Aim II
GAGs play decisive roles in various cancer-associated processes. Changes in the 
expression of GAG fine structures, attributed to deregulation of their biosynthetic and 
catabolic enzymes, are hallmarks of tumor progression and pathogenicity. The wide­
spread role of GAG chains in tumor biology, tumor-associated angiogenesis, and 
metastasis has led to the development of therapeutic agents including enzyme inhibitors, 
modified GAG chains, and GAG binding peptides. Xylosides carrying hydrophobic
aglycone have been known to induce GAG biosynthesis whose composition depends on 
the nature of aglycone. Given the important roles of GAG chains in tumor biology, 
RGD-conjugated xylosides were synthesized to target cells expressing a vp3 integrin, 
including cancer cells and the endothelium surrounding cancer cells, and thereby 
modulate the tumor behavior through induction of GAG chains. Our results demonstrate 
that RGD-conjugated xylosides are able to prime GAG chains in various cell types and 
future studies are aimed toward evaluating potential utility of such xylosides in treating 
myocardial infarction as well as cancer-associated thrombotic complications.
1.2.3. Specific Aim III
Deciphering dynamic changes in GAG structures will provide new avenues to 
diagnose disease states and better understand their dynamic spatio-temporal role in 
developing embryos. Radioactive chemicals are used to label GAG chains in most 
cellular studies; however, they are usually toxic in animal models. Fluorescent xylosides 
may serve as excellent chemical probes to profile cell-specific GAG structures and to 
define the role of GAG chains in various patho-physiological processes. 4-methyl- 
umbellifery-P-D-xyloside is the only known fluorescent molecule that can prime GAG 
chains. However, it makes mostly CS chains of low average molecular weight (< 3000 
Da). Therefore, fluorescent xylosides were synthesized and tested for their priming 
activities of HS and CS in vitro. Our result showed that neither dansyl-xylosides nor 
fluorescein-xylosides primed any detectable GAG chains and pyrene- and umbelliferyl- 
click-xylosides were able to prime GAG with higher average MW than commercial 
umbelliferyl-O-xylosides.
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1.2.4. Specific Aim IV
Most PGs have multiple polysaccharide chains that regulate numerous cell 
signaling events in many biological systems. One distinct structural feature of all PG, 
except decorin, is the covalent linkage of two or more GAG side chains to a core protein. 
The biological significance of GAG multivalency is largely unknown. Previous studies 
have shown that the synergistic biological activity of multivalent GAG chains is not 
accomplished by the sum of the activities of individual chains. Furthermore, it is still 
unclear how multiple GAG chains are assembled onto a given PG. To delineate the 
biological significance of GAG valency and to probe their potential assembly 
mechanism, a library of cluster xylosides carrying two, three, or four xylose residues on 
the same scaffold was designed to induce multiple GAG chains and mimic naturally 
occurring PGs. These results show bis-xylosides primed higher molecular weight GAG 
chains compared to tris- and tetrakis-xylosides. Cluster xylosides prime significant 
CS/DS and less HS on a given scaffold in CHO cells and the distance between xylose 
units affects the priming activity. Multivalent GAG chains, induced by cluster- 
xylosides, can better mimic PGs and therefore can be used as molecular probes to 
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CHAPTER 2
MODULATION OF GAG BIOSYNTHESIS BY CLICK-XYLOSIDES
2.1. Synthesis of Click-xylosides That Initiate GAG Biosynthesis
2.1.1. Introduction
A number of xylosides were studied to further understand the mechanism of 
GAG biosynthesis (1-5). It is observed that the priming activity and composition of 
GAG chains depends on the structure of the aglycone moiety (1-5). However, most of 
the xylosides that were studied made mostly CS and fewer HS. For example, a library 
of P-O-xylosides was examined to stimulate different amounts of CS and DS chains at 
specific concentrations (1-5). However, O-xylosides are considered to be hydrolytically 
unstable in cells. In addition, S- and C-xylosides which are more stable than O- 
xylosides are also shown to prime GAG chains, but only a select few of these xylosides 
were examined in detail (6 ). A library of xylosides with different aglycone groups was 
designed using “click chemistry” because of its high efficiency, regioselectivity, 
biological compatibility, and chemical metabolic/ stability in aqueous/ organic solvents 
(7). Click-xylosides offer two advantages: (1) the 1, 2, 3-triazole ring, generated during 
“click chemistry,” is a metabolically stable linker between xylose residues and 
aglycones and (2 ) the triazole ring can facilitate hydrogen-bonding interactions, 
resulting in favorable and productive biological effects.
2.1.2. Synthesis of Click-xylosides
To define the importance of aglycone structures in GAG priming activity, a 
library of click-xylosides carrying different aglycones (Table 2.1) was synthesized 
using click-chemistry as depicted in Scheme 2.1.
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Table 2.1 Click-xylosides with various aglycone groups
Entry Structure
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Scheme 2.1. Synthesis of click-xylosides
This conjugation approach relies on the Cu(I)-catalyzed orthogonal reaction of 
azide-containing xylosyl scaffold with a terminal alkyne containing aglycone. This 
approach introduces a diverse set of aglycones very quickly and allows one to 
systematically examine the effect of aglycone moieties on the stimulation of GAGs in a 
variety of cellular systems.
Click-xyloside 1: 1H NMR (CD3OD): 5 8.45 (1H, s, triazolyl H), 8.11 ( 1H, d, J  
= 7.8, Ar-H), 7.35 (1H, dd, J  = 7.0, 8 . 6  Hz, Ar-H), 7.11 (1H, d, J  = 8.2 Hz, Ar-H), 7.06 
(1H, dd, J  = 7.4, 8 . 6  Hz, Ar-H), 5.56 (1H, d, J  = 9.4 Hz, H-1), 4.06-4.00 (2H, m, H-2, 
H-5a), 3.96 (3H, s), 3.75-3.68 (1H, m, H-4), 3.54-3.47 (2H, m, H-3, H-5b); Mass (ESI): 
calculated for C14H 18N3O5 308.125, found 307.933
Click-xyloside 2: 1H NMR (CD3OD): 5 8.54 (1H, s, triazolyl H), 7.02 ( 2H, d, J  
= 2.3 Hz, Ar-H), 6.48 (1H, t, J  = 2.3 Hz, Ar-H), 5.54 (1H, d, J  = 9.4 Hz, H-1), 4.03 
(1H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.94 (1H, d, J  = 9.4 Hz, H-2), 3.82 (6 H, s), 3.71-3.67 
(1H, m, H-4), 3.54-3.47 (2H, m, H-3, H-5b); Mass (ESI): calculated for C15H20N3O6 
338.135, found 338.000
Click-xyloside 3: 1H NMR (CD3OD): 5 8.87 (1H, s, triazolyl H), 8.47 ( 2H, s, 
Ar-H), 7.95 (1H, s, Ar-H), 5.59 (1H, d, J  = 9.4 Hz, H-1), 4.05 (1H, dd, J  = 5.5, 11.3 
Hz, H-5a), 3.94 (1H, d, J  = 9.4 Hz, H-2), 3.74-3.68 (1H, m, H-4), 3.55-3.48 (2H, m, H-
3, H-5b); Mass (ESI): calculated for C15H 14F6N3O4 414.089, found 413.933
Click-xyloside 4: 1H NMR (, CD3OD): 5 8.15 (1H, s, triazolyl H), 7.36 (1H, s, 
Ar-H), 7.25-7.34 (3H, m, Ar-H), 5.51 (1H, d, J  = 9.4 Hz, H-1), 4.76 (2H, s), 4.59 (2H, 
s), 4.01 (1H, dd, J  = 5.5, 11. 5 Hz, H-5a), 3.89 (1H, t, J  = 9.4 Hz, H-2), 3.64-3.70 (1H, 
m, H-4), 3.44-3.51 (2H, m, H-3, H-5b); Mass (ESI): calculated for C16H21N3O5N  
374.130, found 374.300
Click-xyloside 5: 1H NMR (CD3OD): 5 7.90 (1H, s, triazolyl H), 7.35 (2H, d, J  
= 7.42 Hz, Ar-H), 7.27 (2H, t, J  = 7.44, Ar-H), 7.20 (1H, t, J  = 7.42 Hz, Ar-H), 5.43 
(1H, d, J  = 9.0 Hz, H-1), 4.22 (2H, s), 3.97 (1H, dd, J  = 5.4, 11.3 Hz, H-5a), 3.82 (1H, t, 
J  = 9.0 Hz, H-2), 3.61-3.67 (1H, m, H-4), 3.40-3.51 (2H, m, H-3, H-5b); Mass (ESI): 
calculated for C14H 18N3O4S 324.100, found 324.000
Click-xyloside 6 : 1H NMR (400 MHz, CD3OD): 5 8.17 (1H, s, triazolyl H), 
7.82-7.84 (4H, m, Ar-H), 7.43-7.48 (3H, m, Ar-H), 5.52 (1H, d, J  = 9.0 Hz, H-1), 4.73 
(2H, s), 4.69 (2H, s), 4.01 (1H, dd, J  = 5. 47, 11.3 Hz, H-5a), 3.90 (1H, t, J  = 8.98 Hz, 
H-2), 3.65-3.71 (1H, m, H-4), 3.44-3.52 (2H, m, H-3, H-5b); Mass (ESI): calculated for 
C19H21N3O5N  394.130, found 394.070
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2.1.3. Priming Activity of Click-xylosides
Most of the previous investigations used O-xylosides and a few ^-xylosides, 
which are metabolically unstable, with the exception of two studies that have examined
stable C-xylosides (1-5). We have synthesized metabolically stable click-xylosides. A 
mutant pgsA-745 cell line, which lacks active xylosyltransferase enzyme, was used to 
test the priming activity of click-xylosides. Since the mutant pgsA-745 cell line does 
not make GAG chains, it requires an exogenous supply of P-xylosides to produce GAG 
chains and thus makes it a convenient cellular system to determine the priming ability 
of exogenously supplied click-xylosides and elucidate the role of aglycone groups (8 ). 
These click-xylosides have been determined to continuously prime GAG chains for at 
least five days. Moreover, migration time of these primed GAG chains for at least five 
days that were analyzed by size exclusion chromatography remained the same. 
Therefore, click-xylosides are metabolically stable (Figure 2.1).
We have examined whether the concentration of xylosides would affect the 
priming activity and determined the optimal primer concentration of each xyloside for 
the maximal production of GAG chains. The priming activity of the xylosides was 
determined as described in the “Experimental Methods” section [2.4] utilizing the 
mutant CHO cell line (pgsA-745) at the following five concentrations: 0.1 |iM, 1 |iM, 
10 |iM, 100 |iM and 1 mM (Figure 2.2).
From the screening experiments with the above concentrations, we were able to 
determine the optimal concentration range for each xyloside for its maximal priming 
activity. The results indicate that the priming is concentration-dependant and 
significant priming for many click-xylosides was observed at a concentration of 1 0 0  
|iM. For the same xylosides, the concentration that was required to observe optimal 
priming activity was higher. The priming activity of the xylosides in this study shows 
that most of the primers generate a significant quantity of GAG chains, although a few
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Figure 2.1. Stability of click-Xylosides. The click-xylosides were examined using 
xylosyl transferase deficient CHO cells (pgsA-745). A. Long-term priming ability of 
GAG chains by click-xylosides at 24, 48, 96, and 120 h. The primed GAG chains were 
quantitated using a liquid scintillation counter. B. Size exclusion profiles of GAG 
chains primed by click-xylosides at 100 |iM concentration in the presence of 50 |iM 
Na23 5SO4. The GAG chains were then purified and quantified as described under 
“Experimental Methods” [2.4]. The results were the average of two independent 
experiments.
are not effective primers. One possible explanation is that the diffusion rates of the 
primers depend on the aglycones that led to differential biosynthesis of the GAG chains. 
However, the click-xylosides 1, 3, 5 and 6  primed more effectively at 100 ^M than they 
did at 1 mM. If diffusion was the only factor that governs priming activity, the priming 
activity would be predicted to be higher at 1mM. However, inhibition of GAG priming 
observed at a higher concentration of xylosides might possibly be due to substrate level
32
Figure 2.2. Priming activity of click-xylosides. The novel xylosides were examined 
for their priming ability using xylosyl transferase deficient CHO cells (pgsA-745). 
100,000 cells were seeded per well of 24-well plates and treated with various xylosides at 
0.1, 1, 10, 100 |iM and 1 mM concentrations for 24 h in the presence of 50 |iCi 3 5S-SO42- 
or D-[6 -3H]-glucosamine. The GAG chains were then purified and quantified as 
described under “Experimental Methods” [2.4].
inhibition of enzymes involved in the assembly of linkage region that would lead to 
reduction in the amount of GAG chains primed. These data clearly suggest that 
differential priming activity among various xylosides does not solely depend on the 
diffusion but also on various factors that are influenced by the aglycones.
2.1.4. Sulfation Patterns of GAG chains Induced by Click-xylosides
DEAE anion exchange chromatography was utilized to compare the extent of 
sulfation of primed GAG chains. GAG chains were recovered from the conditioned 
media by DEAE-sepharose chromatography, followed by isolation of [3 5S]-GAG chains 
as described under “Experimental Methods.” The GAG chains were quantitatively
retained by the column, but they required different concentrations of NaCl for their 
elution. These findings served as a basis to attribute the differences in the elution 
profiles/migration time of various GAG chains on the HPLC anion-exchange column to 
the extent of sulfation of GAG chains primed by various xylosides as described. GAG 
chains that have less sulfate elute at lower ionic strength, whereas heavily sulfated GAG 
chains elute at higher ionic strength. The differences in the elution profiles of the 
primed GAG chains indicate differences in the extent of sulfation among these GAG 
chains. We focused our investigation on HPLC analysis of the GAG chains primed by 
the click-xylosides at the optimal concentration (100 |iM). The sulfate profile of the 
xyloside 1 with a single substituent of -OMe is heterogeneous; however, the sulfate 
profile of the xyloside 2 with a double substituent of -OMe is homogeneous. The 
highly electron withdrawing substituents, -OCF3, also resulted in broad GAG chains 
(Figure 2.3). In this study, we observed a wide variation in the sulfation patterns of 
GAG chains primed by various click-xylosides. This variation in the sulfation patterns 
should be attributed to the presence of discrete enzyme complexes in different Golgi 
subcompartments.
2.2. Inhibition of GAG Biosynthesis by Fluoro-xylosides
2.2.1. Introduction
To elucidate the biological significance of GAG chains, several chemical 
approaches have been employed to inhibit their biosynthesis (9-12). The most 
important ones are sodium chlorate, brefeldin A, and 4-deoxy-glucosamine analogs (10, 
12). Unfortunately, these analogs are not selective inhibitors of GAG biosynthesis
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Figure 2.3. Effect of various hydrophobic moieties on the DEAE elution profiles of GAG chains. GAG chains primed by 
various click-xylosides eluted from analytical anion-exchange column (7.5 mm x 7.5 cm) using linear gradient of 1 M NaCl 
solution. GAG samplers were diluted five-fold prior to analysis by DEAE-HPLC, as described under “Experimental Methods” 
[2.4]. The variations in the elution profiles and migration times indicate differences in both sulfation pattern and extent of sulfation 
of the primed GAG chains. The elution profiles are representative of at least two independent experiments.
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and affect biosynthesis of other glycoconjugates as well. Many xylosides containing 
hydrophobic aglycones act as acceptors for the elongation of GAG chains, as described 
in the previous section.
As an approach to perturb GAG biosynthesis, we propose that 4-deoxy-4-fluoro- 
xylosides (Table 2.2) cannot prime GAG chains as they do not have the acceptor 
hydroxyl group at C-4 position for subsequent sugar attachment and elongation. 
Furthermore, these modified xylosides could affect galactosyl transferase I, an enzyme 
involved in the assembly of linkage region and thereby inhibit the PG biosynthesis 
(Scheme 2.2). Therefore, a library of 4-deoxy-4-fluoro-xyloside was screened to 
determine which scaffolds can selectively and efficiently inhibit the PG biosynthesis in 
a selective manner. We expect that these novel xyloside derivatives will become 
powerful chemical biology tools to define the developmental and physiological actions 
of PG in model organisms by inhibiting or perturbing their biosynthesis in a 
spatiotemporal manner.
2.2.2. Screening of Potential Inhibitor of PG Biosynthesis
We have examined various 4-deoxy-4-fluoro-xylosides, 7-15, for their ability to 
inhibit the PG biosynthesis using wild-type CHO cells as a model cellular system. The 
CHO cells produce both HS and CS chains and therefore, the extent of selective 
inhibition of either HS or CS chains can also be determined. HS and CS chains could 
be resolved and identified using an anion exchange DEAE high-pressure liquid 
chromatography column. Furthermore, elution profiles of GAG chains indicate both the 
extent of sulfate and the sulfation pattern. Thus, GAG chains that have less sulfate elute
36
Table 2.2. Structures of 4-deoxy-4-fluoro-xylosides
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OH
Xyl T1 and Xyl T2: xylosyltransferase-1 and xylosyltransferase-2;
G al T1 and G al T2: galactosyltransferase-1 and galactosyltransferase-2
Scheme 2.2. 4-deoxy-4-fluoro-click xylosides inhibit GAG biosynthesis
at lower ionic strength, whereas heavily sulfated GAG chains elute at higher ionic 
strength. Therefore, we utilized the anion exchange HPLC to deduce whether 4-deoxy- 
4-fluoro-xylosides inhibit PG biosynthesis and the extent of inhibition.
Wild-type CHO cells were grown under conditional media containing 
radioactive Na235SO4 in the absence (control) or presence of various potential inhibitors 
at various concentrations for about 24 h. CHO cells were then subjected to pronase 
treatment and subsequently passed through small disposable DEAE-sepharose columns 
to enrich and elute the radioactive GAG chains. The resulting extract was then 
analyzed using HPLC coupled to an inline radiodetector, as described in the 
“Experimental Methods” [2.4]. GAG chains, composed of both HS and CS chains, 
extracted from cells that are not treated with the inhibitor, migrated between 20-50 
minutes as two peaks. The earlier peak is attributed to HS chains, whereas the later one 
is attributed to CS chains (13). We also observed two very sharp peaks eluting around 5
and 17 minutes. Structural identities of those peaks are unknown. This chromatogram 
served as a control and was utilized to deduce the extent of inhibition of biosynthesis by 
4-deoxy-4-fluoro-xylosides. We then analyzed the extracts from CHO cells that were 
grown in the presence of various inhibitors and compared them against the elution 
profile of GAG chains extracted from control CHO cells. GAG chains from xyloside 7- 
treated cells were shown to have an elution profile that was very identical to that of 
wild-type cells and eluted between 20-50 minutes, suggesting that xyloside 7 is a poor 
inhibitor of PG biosynthesis. On the other hand, xylosides 8 , 9, and 10 were able to 
reduce the amount of GAG chains up to 20 %, suggesting that they are weak inhibitors 
of PG biosynthesis. Xylosides 11, 14, and 15 were able to inhibit approximately 50% 
of total GAG production. Xylosides 12 and 13 were found to be the best inhibitors as 
they reduced about 90% of total GAG chains produced (Figure 2.4).
Dose-response experiments were done to investigate the extent of inhibition of 
biosynthesis by various xyloside derivatives. Cells were treated with inhibitors at 
various concentrations in the presence of 3H-GlcN for 24 h. As shown in Figure 2.5, 
amounts of isolated GAG chains decreased with the increasing concentration of 
xyloside derivatives, 11 and 13. Moreover, it is interesting to note that we did not 
observe any differential effect of these scaffolds on the biosynthesis of HS and CS.
2.2.3. Cytotoxicity of Potential Inhibitor of PG Biosynthesis
Assessment of cell viability is critical before utilizing these novel molecular 
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Figure 2.4. Inhibition of PG  biosynthesis by xyloside derivatives. 35S-Labeled GAG 
chains were isolated from control and 4-deoxy-4-fluoro-xylosides-treated cells as 
described under “Experimental Methods” [2.4]. Radiolabeled GAG chains were then 
fractionated on a DEAE HPLC column and analyzed for radioactivity with the aid of an 
in-line radiometric detector. The bound GAG chains were eluted with a linear gradient of 
1 M NaCl. The elution profiles of GAG chains isolated from cells that were untreated 
(gray trace) or treated (black trace) with PG biosynthetic inhibitors (compounds 7-15) are 
shown above.
after screening xyloside derivatives for their ability to inhibit PG biosynthesis, we 
investigated whether these derivatives are toxic to the cells. Though several methods 
are available, we chose a fluorescent assay, Alamar Blue assay, which is convenient for 
the measurement measurement of cell viability in a reliable and rapid manner. The 
fluorescent dye, used in this assay, is easily soluble in growth media, stable in solution, 
and the least toxic to cells. Cell viability assay confirmed that these xyloside
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Figure 2.5. Dose-dependent decrease of GAG biosynthesis by 4-deoxy-4- 
fluoroxylosides in CHO cells. Samples of 3H-labeled GAG chains from control and 4- 
deoxy-4-fluoroxyloside-treated (compounds 11 (panel A) and 13 (panel B)) CHO cells 
were applied to a DEAE HPLC column, eluted with a linear NaCl gradient starting with 
0.2 M NaCl, as described under “Experimental Methods” [2.4], and analyzed for 
radioactivity with an in-line radiodetector
derivatives are not toxic to cells at various concentrations. However, we observed that 
xylosides 9 and 15 are toxic at 1 mM and higher concentrations to CHO cells (Figure 
2 .6 ).
2.2.4. 4-deoxy-4-fluoro-xylosides Do Not Affect Biosynthesis 
of Glycolipids/ Glycopeptides
These fluorinated xylosides were examined for whether they affect the
biosynthesis of other glycoconjugates such as glycolipids and glycopeptides.(/¥) Cells
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Figure 2.6. Cytotoxicity of 4-deoxy-4-fluoroxylosides. CHO cells were treated with 
different concentrations of xylosides (compounds 7-15) for 24 h and then incubated with 
CellTiter-Blue reagent for 2 h, as described under “Experimental Methods” section, [2.4] 
to estimate the percent of viable cells. CHO cells were grown in the absence of inhibitors 
(vehicle alone) as a control (Control 1), and the values of treated cells were compared with 
Control 1. Cells were also grown in the presence of 3% H2O2 as an additional control 
(Control 2), under which cells were subjected to oxidative stress.
were labeled with [3H] glucosamine in the presence of xyloside derivatives to determine 
whether these scaffolds affect other glycosyltransferases involved in biosynthesis.(/¥) 
Quantitation of [3H]glucosamine-labeled glycolipids extracted from both treated and 
untreated cells suggested that these scaffolds did not affect glycoprotein/glycolipid 
biosynthesis.(/¥) Thus, we can conclude that these scaffolds selectively inhibit GAG 
biosynthesis without affecting other glycol-conjugates.
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2.3. Conclusions
Aglycone groups of xylosides are important in priming activity and induce 
specific structures of GAG chains. This demonstrates that different combinations of 
GAG biosynthetic enzymes in the GAGOSOME may generate cell-specific- 
combinatorial GAG structures with differential sulfation patterns. We also found that 
many of the best stimulatory aglycones of click-xylosides, examined in our earlier 
studies, seem to be essential in the design and construction of potential PG biosynthetic 
inhibitors. Thus, our observation clearly suggests that the hydrophobic nature of 
aglycones is as important as the fluoro atom replacing acceptor the hydroxyl group at 
the C-4 position. It is interesting that these modified xylosides inhibit PG biosynthesis 
to different extents, thus providing novel approaches to fine tune the extent of inhibition 
of PG biosynthesis in the quest to determine the biological consequences of variable 
inhibition in vivo.
2.4. Experimental Methods
2.4.1. General Procedure for the Synthesis of Click-xylosides
Sodium ascorbate (0.1 mmol), followed by Cu2SO4.5H2O (0.01 mmol) were 
added to a solution of alkyne ( 1  mmol) and azide ( 1  mmol) in acetone/ water ( 1 :1 ) at 
room temperature, and the mixture was stirred for 1 2  h (specific time or disappearance 
of one of the starting materials as indicated by TLC). At the end of the reaction, as 
determined by TLC analysis, the mixture was evaporated at reduced pressure to give the 
crude product, which was purified on silica gel column by eluting with ethylacetate/ 
hexane to obtain the desired xyloside derivative.
2.4.2. Deprotection Procedure
A freshly prepared solution of CH3ONa (0.5 M, 0.1 ml) in dry methanol was 
added to a given fully protected xyloside (0.1 mmol) in dry methanol (3 ml), and the 
reaction mixture was stirred at room temperature for about 3 h. Neutralization with H+ 
resin, followed by concentration at reduced pressure gave a syrupy liquid, which was 
then purified on silica gel column to obtain the deprotected xylosides for biological 
evaluation.
2.4.3. General Procedures for Screening Xylosides
To determine whether the xylosides are able to prime the synthesis of GAGs in 
cells in vitro, experiments were performed using CHO pgsA-745. The cells were 
treated with appropriate primers in the presence of 35S-Na2SO4; GAGs were purified 
and analyzed as described below. 1 x 104 cells were plated per well in Ham’s F12 
complete growth medium in a 24-well plate. The cells were incubated at 37 °C in a 
humidified incubator for 24 h to a confluency of about 50%. The cells were washed 
with sterile PBS and replaced with 450 ^L Ham’s F12 containing 10% dialyzed FBS. 
Solutions containing a specific primer at 100X the final concentration were prepared. 5 
^L of appropriate 100X primer were added to various wells to yield a final 
concentration of 100 ^M. 50 ^Ci of 35S-Na2SO4 was also added to each well as tracer. 
The 24-well plates were placed back in the 37 °C incubator for 24 h before the addition 
of 100 ^l 6 X pronase solution, followed by incubation at 37 °C overnight.
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2.4.4. Purification and Quantification of GAG Chains
The entire contents of the wells were transferred to a microcentrifuge tube and 
subjected to centrifugation at 16,000xg for 5 minutes. The supernatant was transferred 
to a fresh tube and half-a-volume of 0.016% Triton X-100 was added. The diluted 
supernatant was loaded on 0.2 mL DEAE-sepharose column pre-equilibrated with 2 mL 
of 20 mM NaOAc buffer pH 6.0 containing 0.1 M NaCl and 0.01% Triton X-100 and 
the column was washed with 4 mL of buffer described above. The bound HS/CS was 
eluted using 1.2 mL elution buffer, 20 mM NaOAc, pH 6.0 containing 1 M NaCl. The 
extent of priming by the various xyloside primers was evaluated by quantifying the 35S- 
radioactivity incorporated into the purified HS/CS elute by liquid scintillation. 50 of 
the various elutes were added to 5 mL of scintillation cocktail and the vials were 
counted in a scintillation counter in triplicate. The amount of radioactivity corresponds 
to the total GAG synthesized by the primer.
2.4.5. HPLC Analysis of GAGs
The purified GAGs were analyzed by HPLC with an inline radiodetector. 50 ^l 
of elute was diluted five times with the HPLC solvent A (10 mM KH2PO4, pH 6.0, 0.2 
% CHAPS) and loaded on to a weak anion exchange column, DEAE-3SW (TosoHaas 
Inc.), and analyzed with the following elution profile. The sample was eluted from the 
column with a linear gradient of 0.2 M NaCl at 0 minute to 1 M NaCl at 80 minutes at a 
flowrate of 1 ml per minute. The radioactive GAGs were detected by a Radiomatic flo- 
one A505A radio-chromatography detector. The HPLC effluent was mixed with
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Ultima-Flo AP scintillation cocktail in a 2:1 ratio and detected in the flow scintillation 
detector.
2.4.6. Cell Viability Assay
CHO-K1 cells were examined for viability in the presence of 4-deoxy-4- 
fluoroxyloside derivatives using CellTiter-Blue reagent (Promega). Cells were seeded 
into duplicate wells of a 96-well plate at a density of 2.5x104 viable cells/well in 125 ^l 
of Ham’s F-12 complete growth medium supplemented with 10% fetal bovine serum 
and grown for 24 h with vehicle alone or xyloside derivatives. Cells were also treated 
with 3% H2O2 as an additional control for the cell viability assay. After 24 h of 
treatment with vehicle, H2O2, or xyloside derivative, 25 ^l of CellTiter- Blue reagent 
was added to each well according to the manufacturer’s protocol. After incubation in 
the humidified incubator for 2  h, the fluorescence generated in the assay was then 
stopped and stabilized by addition of 50 ^l of 3% SDS solution. The fluorescence was 
immediately measured using a Spectra- Max M5 microplate reader (Molecular Devices, 




Figure S2.1. NMR spectra of click-xyloside 1
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Figure S2.2. Mass spectra of click-xyloside 1
Figure S2.3. NMR spectra of click-xyloside 2
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Figure S2.4. Mass spectra of click-xyloside 2
Figure S2.5. NMR spectra of click-xyloside 3
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Figure S2.6. NMR spectra of click-xyloside 4
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Figure S2.7. Mass spectra of click-xyloside 4
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CHAPTER 3
DESIGN OF FLUORESCENT XYLOSIDES TO PRO FILE 
CELL-SPECIFIC  GAG CHAINS
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3.1. Introduction
PGs modulate numerous pathophysiological functions such as development (1­
7), angiogenesis (8-12), axonal growth (13), anticoagulation (14-18), cancer progression 
(19, 20), microbial pathogenesis (21-25), etc. The quantity and quality of GAG 
structures, made by various cells, are dynamically regulated in a spatio-temporal 
manner during the development of an organism and during the normal aging of an 
organism, as well as during the progression of several pathological conditions. 
Profiling and deciphering dynamic changes in GAG structures will provide new 
avenues to diagnose disease states and may thwart those conditions with novel 
therapeutics (26). Most of these structural changes have been deduced using 
radiolabeled monosaccharides and sulfate as biosynthetic precursors in various cellular 
systems. However, these radiolabeled precursors cannot be used in organisms as they 
pose toxicity and other challenges. Several P-xyloside derivatives have been shown to 
act as acceptors and substitute for core proteins in vivo as well as in vitro in the 
production of core protein free GAG chains (27-36). Fluorogenic xylosides that are 
able to prime GAG chains will be an excellent tool to study the structure-function 
relationship in vivo. Commercial 4-methyl-umbelliferyl-P-D-xyloside (UMB-O- 
xyloside) has been shown until now to function as acceptor for the elongation of GAG 
chains; however, UMB-O-xylosides prime mostly CS chains or small oligossacharides 
(37-39). Earlier studies examined several fluorescently labeled xylosides that were 
unable to prime GAG chains (40). Our efforts are, therefore, focused on the synthesis 
and screening of fluorescent tagged xylosides for their ability to prime GAG chains in a 
given cellular system and provides novel avenues to profile and elucidate cellular GAG
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signatures in a robust manner, and assist in establishing cell-specific GAG-protein 
interactions.
3.2. Results and Discussion
Several fluorescent tagged xylosides were synthesized and are examined for 
whether these fluorescent tagged xylosides can elongate GAG chains. In the future, 
these fluorescent xylosides offer prospects to further our understanding of factors that 
regulate GAG biosynthesis as well as new knowledge on the role of GAG chains in 
various signaling events associated with pathophysiological processes.
3.2.1. Synthesis of Fluorescent Tagged Xylosides
Several studies proved that stimulation of GAG chains is not only affected by 
hydrophobic aglycones of xylosides but also by their glycosidic linkages (27-36). 
Therefore, several fluorescent xylosides with amide and triazole in the glycosidic 
linkage were synthesized in this study. N-(2, 3, 4-trihydroxyl-P-xylopyranosyl) 
acetamide 5 was synthesized from xyloside azide as outlined in Scheme 3.1. Xylose 
was converted to xylosize azide 1 , which was then coupled with chloroacetic anhydride 
to prepare the xyloside 2 (41). The chloro group in xyloside 2 was replaced with the 
azido group by treating xyloside 2 with NaN3 to obtain the xyloside 3.(41) The azide 
group containing xyloside was then deprotected and reduced to obtain the xyloside 5 
(42, 43). Fluorogenic xylosides (6 , 7, and 8 ) were synthesized from corresponding 
commercially available activated fluorescent reagents (dansyl Chloride, FITC, and N- 
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Scheme 3.1. Synthesis of amino-N-(2, 3, 4-trihydroxyl-p-xylopyranosyl) acetamide
the reactive amine group (Scheme 3.2). Activated fluorescent probes are conjugated 
with xyloside amine to obtain the fluorescent conjugated xylosides in a rapid manner. 
Unfortunately, xyloside amine was unstable in our hands and therefore, the strategy 
outlined in Scheme 3.1 was chosen to introduce the reactive amine group.
It is known that the linker between xylose and the aglycone moiety (fluorogenic 
tag in this case) may dramatically influence the priming activity. Therefore, a second 
strategy was devised in which xylose was differentially attached to fluorescent tags by 
reacting xyloside azide 1  with triple bond containing fluorescent tags using click 
chemistry as shown in Scheme 3.3 (44). Xyloside 10 with a triozyl linkage is prepared, 
which contains the reactive amine group for conjugating with activated fluorescent 
reagents to obtain the fluorogenic xyloside 1 2 .
The commercial well-known UMB-O-xyloside primes mostly short chains of 
GAG chains or oligossacharides in various cell types (37-39, 45). Click chemistry was 
used to conjugate fluorescent UMB derivatives 13a and 13b to the xylose unit. Fully 
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Scheme 3.3. Synthesis of fluorogenic xylosides with triazole linkages
these UMB-click-xylosides were deprotected under Zemplen condition to obtain the 
final products 16a and 16b, as outlined in Scheme 3.4. All final products were purified 
on a reverse phase C18 column using HPLC as described in the experimental section, 
followed by structural analysis using NMR spectrometer and mass spectrometry.
Compound 2: !H NMR (CD3Cl): 5 5.32 (t, J  = 9.4 Hz, 1H), 5.12 (dd, J  = 9.0, 9.4 
Hz, 1H), 5.02-4.95(m, 1H), 4.94 (t, J  = 9.4 Hz, 1H), 4.10 (dd, J  = 5.5, 11.5 Hz, 1H),
4.03 (d, J  = 7.4 Hz, 2H), 3.46 (t, J  = 11.14 Hz, 1H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 
3H).
Compound 3: 1H NMR (CD3Cl): 5 5.31 (t, J  = 9.4 Hz, 1H), 5.12 (t, J  = 9.4 Hz, 
1H), 4.98-4.95 (m, 1H), 4.90 (t, J  = 9.4 Hz, 1H), 4.09 (dd, J  = 5.9, 11.5 Hz, 1H), 4.00 
(d, J  = 5.47 Hz, 2H), 3.45 (t, J  = 11.7 Hz, 1H), 2.07 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H).
Compound 4: 1H NMR (CD3Cl): 5 4.84 (d, J  = 8 .6  Hz, 1H), 3.90 (d, J  = 5.9 Hz, 
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Scheme 3.4. Synthesis of UMB-click-xylosides with triazole-linkages
Compound 5: !H NMR (CD3CI): 5 4.84 (d, J  = 8.98 Hz, 1H), 3.82 (dd, J  = 5.1, 
11.33 Hz, 1H), 3.59 (s, 2H), 3.50-3.44 (m, 1H), 3.37-3.23 (m, 3H).
Compound 6 : 1H NMR (CD3OD): 5 8.57 (d, J  = 8 .6  Hz, 1H), 8.34 (d, J  = 9.0 
Hz, 1H), 8.20 (d, J  = 7.45 Hz, 1H), 7.60 (t, J  = 8.0 Hz, 1H), 7.57 (t, J  = 8.0 Hz, 1H), 
7.28 (d, J  = 7.8 Hz, 1H), 4.70 (d, J  = 9.0 Hz, 1H), 3.75 (dd, J  = 5.1, 11.3 Hz, 1H), 3.56 
(d, J  = 3.9 Hz, 2H), 3.44-3.37 (m, 1H), 3.20-3.05 (m, 3H), 3.89 (s, 6H); Mass (ESI): 
calcd for C 19H24N 3O7S [M-H]- 438.475, found 438.310.
Compound 7: 1H NMR (CD3OD): 5 8.52 (s, 1H), 8.18 (d, J  = 2.0 Hz, 1H), 7.81 
(dd, J  = 2.0, 8.2 Hz, 1H), 7.16 (d, J  = 8.2 Hz, 1H), 6.83 (d, J  = 8 .6  Hz, 2H), 6.67 (d, J  =
2.4 Hz, 1H), 6.57 (dd, J  = 2.3, 8 .6  Hz, 2H), 4.38 (d, J  = 11.3 Hz, 1H), 3.85 (d, J  = 5.1,
11.3 Hz, 1H), 3.50-3.46 (m, 1H), 3.39-3.24 (m, 3H), 3.89 (s, 6H); Mass (ESI): calcd for 
C28H26N 3O 10S [M+H]+ 596.134, found 596.139.
Compound 8 : 1H NMR (CD3OD): 5 8.37 (d, J  = 9.4 Hz, 1H), 8.19-8.13 (m, 4H), 
8.04-7.97 (m, 3H), 7.92 (d, J  = 7.8 Hz, 1H), 3.91 (dd, m, 2H), 3.80 (dd, J  = 5.1, 11.1 
Hz, 1H), 3.48-3.21 (m, 7H), 2.44 (t, J  = 7.4 Hz, 2H), 2.21-2.16 (m, 2H); Mass (ESI): 
calcd for C27H28N 2O6N  [M+Na]+ 499.185, found 499.067.
Compound 12a: 1H NMR (CD3OD): 5 8.55 (d, J  = 8 .6  Hz, 1H), 8.32 (d, J  = 8 .6  
Hz, 1H), 8.20 (d, J  = 7.4 Hz, 1H), 7.64 (s, 1H), 7.58 (dd, J  = 7.8, 10.2 Hz, 1H), 7.56 
(dd, J  = 7.4, 8 .6  Hz, 1H), 7.27 (d, J  = 7.42 Hz, 1H), 5.34 (d, J  = 9.0 Hz, 1H), 4.17 (s, 
2H), 3.96 (dd, J  = 5.5, 11.4 Hz, 1H), 3.68 (t, J  = 9.0 Hz, 1H), 3.66-3.58 (m, 1H), 3.45­
3.38 (m, 2H), 3.89 (s, 6H); Mass (ESI): calcd for C20H25N 5O6S N  [M+Na]+ 486.142, 
found 486.200.
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Compound 12b: !H NMR (CD3OD): 5 8.16 (2H, d, J  = 16.4 Hz), 7.74 (1H, d, J  
= 8.2 Hz), 7.15 (1H, d, J  = 8.2 Hz), 6 .6 6  (3H, d, J  = 2.0 Hz), 6.53 (2H, d, J  = 8 .6  Hz), 
5.50 (1H, d, J  = 9.4 Hz), 4.96 (2H, s), 3.90 (1H, dd, J  = 5.0 , 11.1 Hz), 3.88 (1H, t, J  = 
8 .6  Hz), 3.70-3.63 (1H, m), 3.50-3.42 (2H, m); Mass (ESI): calcd for C29H24N 5O9SNa 
[M-H+Na]+ 641.137, found 641.333
Compound 12c: 1H NMR (CD3OD): 5 8.27-7.84 (m, 10H), 5.46 (d, J  = 9.4 Hz, 
1H), 4.45 (d, J  = 2.3 Hz, 1H), 3.95 (dd, J  = 5.5, 11.3 Hz, 1H), 3.86 (t, J  = 8.4 Hz, 1H), 
3.67-3.57 (m, 3H), 3.49-3.39 (m, 2H), 2.35 (round, 2H), 2.12 (round, 2H). Mass (ESI): 
calcd for C28H28N 4O5N  [M+Na]+ 523.196, found 523.130.
Compound 14a: 1H NMR (CDCh): 5 7.53 (d, J  = 8.99 Hz, 1H), 6.95 (s, 1H), 
6.93 (d, J  = 2.7 Hz, 1H), 6.17 (d, J  = 1.2 Hz, 1H), 4.77 (d, J  = 2.3 Hz, 2H), 2.58 (t, J  =
2.3 Hz, 1H), 2.41 (s, 3H).
Compound 14b: 1H NMR (CDCh): 5 7.64 (d, J  = 8.2 Hz, 1H), 6.99 (s, 1H), 6.97 
(d, J  = 2.0 Hz, 1H), 6.63 (s, 1H), 4.78 (d, J  = 2.3 Hz, 2H), 2.59 (t, J  = 2.3 Hz, 1H).
Compound 16a: 1H NMR (CD3OD): 5 8.30 (s, 1H), 7.70 (d, J  = 9.6 Hz, 1H),
7.05 (s, 1H), 7.03 (s, 1H), 6.17 (s, 1H), 5.53 (d, J  = 9.0 Hz, 1H), 5.29 (2H, s), 4.00 (dd, 
J  = 5.5, 11.3 Hz, 1H), 3.90 (t, J  = 9.0 Hz, 1H), 3.70-3.64 (m, 1H), 3.52-3.44 (m, 2H), 
2.44 (s, 3H), Mass (ESI): calcd for C ^ H ^ O y N a  [M+Na]+ 412.122, found 412.200
Compound 16b: 1H NMR (CD3OD): 5 8.32 (s, 1H), 7.69 (d, J  = 9.0 Hz, 1H), 
7.17 (d, J  = 2.3 Hz, 1H), 7.10 (dd, J  = 2.3, 9.0 Hz, 1H), 6.71 (s, 1H), 5.54 (d, J  = 9.0 
Hz, 1H), 5.33 (2H, s), 4.00 (dd, J  = 5.5, 11.3 Hz, 1H), 3.90 (t, J  = 9.0 Hz, 1H), 3.71­




3.2.2. Screening of Fluorogenic Xylosides
The priming activity of these novel xylosides may perhaps be attributed to the 
presence of a very hydrophobic fluorescent group, helping their transport across cell 
surface and Golgi membranes to GAGOSOMEs. The priming ability of fluorescent- 
tagged xylosides are investigated using a mutant Chinese hamster ovary (CHO) cell 
line, pgsA-745, which lacks active xylosyltransferase enzyme (46). This cell line does 
not make GAG chains. It requires the exogenous supply of P-xylosides to produce 
GAG chains, and is thus a convenient cellular system to ascertain the quantity of the 
primed GAG chains by exogenously supplied fluorescent xylosides. Neither dansyl 
group attached xylosides (6  and 12a) nor fluorescein attached xylosides (7 and 12b) 
primed any detectable GAG chains. It may perhaps be due to the presence of charged 
amine (in dansyl moiety) and carboxyl (in fluorscein moiety) groups preventing the 
uptake of xylosides across the cell membrane. This is in accordance with Mani et al. 
who found out that the dansyl group attached xylosides were unable to prime any 
detectable amount of GAG chains. Fluorescent xylosides without a charged group are 
chosen to be synthesized. Fluorescent xylosides (8 , 12c, 16a and 16b), in which xylose 
residue is attached to 1-pyrene butyrate and UMB derivatives, were synthesized. 
Pyrene containing xyloside with amide linkages 8  were not able to prime GAG chains 
while the pyrene containing xyloside with triazoyl linkage 12c were able to prime at 50 
|iM and 100 |iM (Figure 3.1).
It is interesting to observe that the pyrene containing xyloside with triazole 
linkage 12c can prime GAG chains but the pyrene containing xyloside with amide 
linkage 8  cannot prime GAG chains. Therefore, the triazole ring may increase
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Figure 3.1. Prim ing activity of fluorescent xylosides (12c and 8 ) in pgsA-745 cell 
line. CHO cells were treated with fluorescent xylosides at 50 |iM and 100 |iM in the 
presence of 3H (100 |iCi) as described in “Experimental Methods” section [5.4]. The 
GAG chains were purified by anion exchange chromatography and quantitated using a 
liquid scintillation counter. The results were the average of two independent 
experiments
the diffusion rate and direct the primer to Golgi compartments. Next, UMB-click- 
xylosides 16a and 16b were designed and compared to the commercial UMB-O- 
xylosides that prime mostly GAG chains with a low chain length. The priming 
activities of the UMB-click-xylosides 16a and 16b and the commercial xyloside were 
compared at various concentration (50 |iM, 100 |iM, 300 |iM, 600 |iM, and 1 mM) 
(Figure 3.2). It is interesting to note that priming activity of the UMB-click-xylosides 
16a and 16b was concentration-dependent but the UMB-O-xyloside was not.
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Figure 3.2. Prim ing activity of UMB-click-xylosides (16a, 16b), and UM B-0- 
xylosides (control) in pgsA-745 cell line. CHO cells were treated with fluorescent 
xylosides at 50 |iM, 100 |iM, 300 |iM, 600 |iM, and 1 mM in the presence of 3H(100 
|iCi) as described in the “Experimental Methods” section [5.4]. The GAG chains were 
purified by anion exchange chromatography and quantitated using a liquid scintillation 
counter. The results were the average of two independent experiments
3.2.3. Structural Analysis of Primed GAG Chains
The GAG chains primed by these fluorescent xylosides 12c, 16a and 16b were 
further analyzed for their sulfation pattern by the DEAE-anion exchange HPLC column 
and for their molecular weights using size exclusion columns, as outlined in the 
“Experimental Methods” section [5.4]. GAG chains primed by xyloside 12c at 50 |iM 
is more homogenous and has higher sulfate than at 100 |iM (Figure 3.3). The chain 
length of GAG chains primed by fluorescent xyloside 12c in CHO cells was determined 
by measuring migration time of GAG chains in comparison to those of polystyrene 
sulfonate standards performed under similar conditions on the size exclusion column 
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Figure 3.3. Sulfate density profile of fluorescent xyloside 12c prim ed GAG chains.
GAG chains primed by fluorescent xyloside 12c in pgsA-745 cell lines at 50 |iM and 
100 |iM were analyzed using anion exchange HPLC: the bound GAG chains were 
eluted with a linear gradient from 0.2 M to 1 M NaCl over 80 minutes at a flow rate of 
1ml/ min. These elution profiles are representative of two independent experiments.
an 27 KDa at 50 |iM and 20 KDa at 100 |iM (Figure 3.4). We have estimated the 
percentage compositions of HS and CS chains in the total GAG pool. Unfortunately, 
fluorescent xyloside 12c primed mostly CS (up to 95 %). Moreover, the fluorescent 
xyloside 12c was not sensitive enough. Therefore, the structural analysis of GAG 
chains primed by the fluorescent xyloside 1 2 c could not be studied using fluorescent 
detectors.
The UMB-O-xyloside has been shown to function as acceptor for the elongation 
of GAG chains by several groups (37-39). However, this well-known fluorescent 
xyloside mostly prime CS with low MW chains. By changing the O linkage of the 
fluorescent xyloside to click linkage, the fluorescent click-xylosides were hoped to 
prime both HS and CS with higher MW chains. The results from priming activity
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Figure 3.4. Size exclusion profiles of GAG chains prim ed by fluorescent xyloside 
12c. GAG chains primed by fluorescent xyloside 12c at 50 |iM and 100 |iM 
concentrations in pgs A-745 cells for 24 h. The purified GAG chains were analyzed by 
size exclusion chromatography, fractionated on two tandem 3000 S W x l  columns, and 
was eluted with an isocratic gradient of phosphate buffer for 90 minutes at a flow rate of 
0.5 ml/ min.
analysis suggest that optimized priming concentration of UMB-click-xyloside 16a and 
16b is300 |iM. Therefore, the GAG chains primed by these xylosides at 300 |iM were 
further analyzed for their molecular weight using the size exclusion column and HS/ CS 
composition using heparin lyases I, II, and III (Figure 3.5). It notes that both 
fluorescent xylosides 16a and 16b primed GAG chains have an average molecular 
weight (42 KDa) is higher than those primed by commercial UMB-O-xyloside (4KDa). 
Moreover, it is surprising to note that fluorescent xylosides 16a and 16b primed about 
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Figure 3.5. Size exclusion profiles of GAG chains prim ed by fluorescent xylosides 
(UMB-O-xyloside, 16a and 16b). GAG chains primed by fluorescent xylosides at 300 
|iM concentration in pgsA-745 cells for 24 h. The HS/CS composition of the primed 
GAG chains was determined by digesting the GAG chains with heparin lyases I, II, III. 
The enzyme reaction and the purification of the primed GAG chains were described in 
the “Experimental Methods” section [5.4]. The purified GAG chains were analyzed by 
size exclusion chromatography, fractionated on two tandem 3000 SWXL columns, and 
were eluted with an isocratic gradient of phosphate buffer for 90 minutes at a flow rate 
of 0.5 ml/ min. A: The elution profiles of GAG chains primed by UMB-O-xyloside. B: 
The elution profile of GAG chains primed by fluorescent xyloside 16a. C: The elution 
profiles of GAG chains primed by fluorescent xyloside 16b.
3.3. Conclusions
In conclusion, a small library of novel fluorescent xylosides was synthesized to 
evaluate their GAG-priming activity and structural analysis. Pyrene- and UMB-click- 
xylosides were able to participate in the stimulation of GAG biosynthesis. These 
fluorescent xylosides containing the triazyol rings were more stable than commercially 
available xylosides and predictably have a longer in vivo half life. Moreover, these 
fluorescent xylosides were able to prime more HS and higher MW than commercial 
fluorescent xylosides. Therefore, these xylosides have potential to profile and elucidate 
cellular-specific heparanome to define various dynamic interactions in the complex 
systems and to offer prospects to further our understanding of factors that regulate GAG
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biosynthesis as well as new knowledge on the role of GAG chains in various signaling 
events associated with pathophysiological processes.
3.4. Experim ental M ethods
3.4.1. General Synthetic Procedures
All chemical reactions were carried out under a nitrogen atmosphere in oven- 
dried glassware using standard techniques. 1H and 13C NMR spectra were obtained on a 
bruker 400-MHz spectrometer. Chemical shifts are relative to the deuterated solvent 
peak or the tetramethylsilane (TMS) peak at (5 0.00) and are in parts per million (ppm). 
High-resolution mass spectrometry (HRMS) was performed using a Finnigan LCQ 
mass spectrometer in either positive or negative ion mode. Thin layer chromatography 
(TLC) was done on 0.25 mm thick precoated silica gel aluminum sheets. 
Chromatograms were observed under short and long wavelength UV light, and were 
visualized by heating plates that were dipped in a solution of Von’s reagent containing 
ammonium (VI) molybdate tetrahydrate (12.5 g) and cerium (IV) sulfate tetrahydrate 
(5.0 g) in 10% aqueous sulphuric acid (500 mL). Flash column chromatography was 
performed using silica gel 60 (230-400 mesh) and employed a stepwise solvent polarity 
gradient, correlated with TLC mobility, and were run under pressure of 5-7 psi. HPLC 
was used to purify final products using C18 column (VYDAC 2.2 cm x25cm) with 
solvent A (25mM formic acid) and solvent B (95% Acetonitrile) at a flow rate of 5 ml/ 
minutes in a linear gradient over 120 minutes starting with 0% B.
2, 3, 4-Tri-O-acetyl-D-xylopyranosyl azide (1): Trimetylsilyl azide (1.5 mmol) 
and SnCl4 (0.5 mmol) were added dropwise to a stirred solution of fully acetylate
xylose derivative (1mmol) in dry CH2Cl2, and stirring was continued at room 
temperature. The progress of the reaction was checked by TLC, and after the 
completion of the reaction, the reaction mixture was then evaporated under vacuum to 
give a residue that was further purified by low pressure flash silica column 
chromatography to yield the compound 1 .
N-(2,3,4-tri-O-acetyl-P-D-xylopyranosyl) chloroacetamide (2): 2,3,4-Tri-O- 
Acetyl-P-D-xylopyranosyl azide (1) (1 mmol) was dissolved in dry CH2Cl2 (20 ml). 
The mixture was cooled at 0°C. Chloroacetic anhydride (1 mmol) was added to the 
solution, followed by triphenyl phosphine ( 1  mmol), and the reaction was continued 
overnight. After the reaction was complete, the solvent was removed using rotary 
evaporator under reduced pressure. The reaction mixture was extracted using ethyl 
acetate and water. The organic layer was washed with saturated brine solution and 
evaporated under vacuum to give a residue, which was purified by silica column 
chromatography to give the title compound 2 .
N-(2,3,4-tri-O-acetyl-P-xylopyranosyl) azidoacetamide (3): N-(2,3,4-tri-O- 
acetyl-P-D-xylopyranosyl) chloroacetamide (2) (1 mmol) was taken in a 100 ml RB 
flask and dry DMF (20 ml) was added, followed by the addition of sodium azide (2 
mmol). The reaction mixture was heated to 90°C under stirring. Progress of the 
reaction was monitored by TLC using ethyl acetate and hexane (1:1) as the eluant. 
After the reaction was complete, the reaction mixture was cooled and diluted with ethyl 
acetate. The organic layer was washed with water, dried over sodium sulfate, and 
concentrated to obtain a syrupy material that was further purified by silica flash column 
chromatography to give the title compound 3.
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N-(P-D-xylopyranosyl) azidoacetamide (4): N-(2,3,4-tri-O-acetyl-P- 
xylopyranosyl) azidoacetamide (3) (0.1 mmol) was taken in dry methanol and was 
treated with freshly prepared 0.5 M solution of CH3ONa (0.1ml) in dry methanol at 
room temperature for 3 h. Neutralization with H+ resin followed by concentration at 
reduced pressure gave a syrupy liquid, which was purified by silica flash column 
chromatography to give the title compound 4.
N-(P-D-xylopyranosyl) aminoacetamide (5): A solution of N-(P-D- 
xylopyranosyl) azidoacetamide (4) (0.1 mmol) in dry methanol (10 ml) was 
hydrogenated over Pd/C (0.1 mmol) for 1 h. After the strating material disappeared 
(TLC), the catalyst was removed by filtration through celite and washed with methanol 
(10 ml). The filtered solution was concentrated by rotovapor to get the final product 5 
without purification steps.
Synthesis of fluorophore tagged xylosides with amide linkages (6 , 7 and 8 ): N- 
(P-D-xylopyranosyl) aminoacetamide 5 (0.1 mmol) was dissolved in dry DMF (10 ml). 
Dissopropylethylamine (0.1 mmol) was added. The whole mixture was stirred for 30 
minutes before adding the commercially available activated fluorescent reagents 
(Dansyl chloride, FITC and N-hydroxysuccinimidyl-1-pyrene butyrate) (1 mmol). The 
reaction mixture was stirred for 4 h and purified by C18-HPLC column.
N-(P-D-xylopyranosyl) azide (9): 2, 3, 4-Tri-O-acetyl-P-D-xylopyranosyl azide 
1 (0.1 mmol) was taken in dry methanol and was treated with freshly prepared 0.5 M 
solution of CH3ONa (0.1ml) in dry methanol at room temperature for 3 h. 
Neutralization with H+ resin followed by concentration at reduced pressure gave a
syrupy liquid, which was purified by silica flash column chromatography to give the 
title compound 9.
Propargyl UMB derivative (14): To the solution (10ml ) of UMB derivative (13a 
and 13b) (1 mmol) in acetone, was added potassium carbonate (3 mmol). The reaction 
mixture was stirred for 30 minutes at room temperature. Propargyl bromide (3 mmol) 
was then added and the mixture was stirred overnight. The reaction mixture was 
concentrated. The resulting crude material was dissolved in ethyl acetate, washed with 
water and saturated sodium chloride solution, dried over Na2SO4 and rotary evaporated 
under reduced pressure. The residue was purified by column chromatography to give 
the compound 14.
Synthesis of fluorophore tagged xylosides with click linkages (12a, 12b, 12c, 
15a and 15b): to a solution of alkyne (1mmol) and azide (1mmol) in DMF and water 
(4:1.3) solvent mixture were added sodium ascobate (0.8 mmol) followed by Cu2SO4. 
5H20 (0.4 mmol) at room temperature, and the mixture was stirred for 12 h or until 
disappearance of one of the starting materials as indicated by TLC. At the end of the 
reaction as confirmed by TLC analysis, the solvent of the reaction mixture was 
evaporated using rotary-evaporator under reduced pressure. The reaction mixture was 
purified by flash chromatography columns as described above. The purified acetylated 
product (0.1 mmol) was taken in dry methanol and was treated with freshly prepared 0.5 
M solution of CH3ONa (0.1ml) in dry methanol at room temperature for 3 h. 
Neutralization with H+ resin followed by concentration at reduced pressure gave a 
syrupy liquid, which was purified on HPLC using C18 column to give the desired 
deprotected xyloside derivatives.
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3.4.2. Screening of Fluorescent Xylosides in Cell Culture
The priming of the xylosides in xylosyl transferase-deficient CHO cell line 
pgsA-745 was performed as described in our earlier communication. Briefly, 1x105 
cells were plated per well, containing the appropriate complete growth medium, in a 24- 
well plate and incubated at 37 °C in a humidified incubator for 24 h to reach a 
confluency of about 50%. The cells were then washed with sterile PBS and replaced 
with 450 appropriate medium containing 10% dialyzed FBS. A serial dilution of the 
primers at 100X the final concentration was prepared and 5 ^L of appropriate 100X 
primer was added to various wells to yield a final concentration of 0 . 1  1 , 1 0 , 1 0 0 , and 
1000 ^M, respectively. 50 ^Ci 6 -3H-glucosamine was then added to each well for 
radiolabeling the GAG chains synthesized. The 24-well plates were placed in the 
incubator for 24 h before the addition of 6 X pronase solution (100 ^L) followed by 
incubation at 37 °C overnight.
3.4.3. Purification and Quantification of GAGs
After treating each well with pronase solution overnight, the entire contents of 
the wells were transferred to a microcentrifuge tube and subjected to centrifugation at 
16,000xg for 5 minutes. The supernatant was transferred to a fresh tube and half-a- 
volume of 0.016% Triton X-100 was added. The diluted supernatant was loaded on to a 
DEAE-sepharose column (0.2 mL) pre-equilibrated with 10 column volumes of wash 
buffer (20 mM NaOAc buffer (pH 6.0) containing 0.1 M NaCl and 0.01% Triton X- 
100) and the column was washed with 20 column volumes of wash buffer. The bound 
HS/CS was eluted using 6  column volumes elution buffer (20 mM NaOAc (pH 6.0)
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containing 1 M NaCl). The amount of GAG primed by various “Click”-xylosides was 
determined by quantifying the 3H-radioactivity incorporated in the purified HS/CS 
eluate. 50 ^L of the various eluates was diluted with 5 mL of scintillation cocktail and 
triplicate samples were measured using a scintillation counter for total radioactivity.
3.4.4. Analysis of Primed GAG Chains
The homogeneity and extent of sulfation of the GAG chains synthesized on the 
various primers was determined by measuring migration time on the anion exchange 
column using high-pressure liquid chromatography (HPLC) with inline radiodetector. 
25 ^L of eluate was diluted 10-fold with 10 mM KH2PO4 (pH 6.0) containing 0.2 % 
CHAPS, and loaded onto a DEAE column and eluted with a linear NaCl gradient of 0.2 
to 1 M over 80 minutes.
The chain length of the primed GAG was determined by measuring the 
migration time on two tandem G3000SWXL (Tosoh, 7.8 mm x 30 cm) size exclusion 
columns using the HPLC Hitachi system with an inline radiodetector or fluorescent 
detector. The solvent containing phosphate (100 mM KH2PO4, 100 mM NaCl, pH 6 ) 
was used as an eluent. The average molecular weight was determined by measuring the 
migration time of GAG chains in comparison to those of polystyrene sulfonate 
standards examined under similar conditions.
The HS/CS composition of the primed GAG chains was determined by digesting 
the GAG chains with heparitinase I/II/III or chondroitinase ABC enzymes. The 
solution containing GAGs was diluted to 0.2 M NaCl, followed by the addition of 
heparitinase or chondroitinase ABC buffer and 5 mU of heparitinase I/II/III or
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chondroitinase ABC enzyme. The reaction mixture was incubated at 37 °C for 2 h, the 
solution was then loaded on to two tandem G3000 SWXL columns (7.8 mm x 30 cm) 
and analyzed with the aid of an inline radiometric detector using phosphate buffer ( 1 0 0  
mM KH2PO4, 100 mM NaCl, pH 6 ) as an eluent. The percentage of HS/CS was 
determined based on the percentage area of undigested and digested GAG peaks.
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3.5. Supporting Inform ation
Figure S3.1. NMR spectra of fluorescent xyloside 6
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Figure S3.2. NMR spectra of fluorescent xyloside 7
08
Figure S3.3. NMR spectra of fluorescent xyloside 8
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Figure S3.6. NMR spectra of fluorescent xyloside 12b
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Figure S3.7. NM R spectra of fluorescent xyloside 12c
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Figure S3.9. Mass spectra of fluorescent xyloside 16a




Figure S3.11. Mass spectra of fluorescent xyloside 16b
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Abstract Glycosaminoglycans (GAG) play decisive roles 
in various cardio-vascular & cancer-associated processes. 
Changes in the expression o f  GAG fine structures, 
attributed to deregulation o f their biosynthetic and catabolic 
enzymes, are hallmarks o f vascular dysfunction and tumor 
progression. The wide spread role o f GAG chains in blood 
clotting, wound healing and tumor biology has led to the 
development o f modified GAG chains, GAG binding 
peptides and GAG based enzyme inhibitors as therapeutic 
agents. Xylosides, carrying hydrophobic aglycone, are 
known to induce GAG biosynthesis in various systems. 
Given the important roles o f GAG chains in vascular and 
tumor biology, we envision that RGD-conjugated xylosides 
could be targeted to activated endothelial and cancer cells, 
which are known to express a v(33  integrin, and thereby 
modulate the pathological processes. To accomplish this 
vision, xylose residue was conjugated to linear and cyclic
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RGD containing peptides using click chemistry. Our results 
demonstrate that RGD-conjugated xylosides are able to 
prime GAG chains in various cell types, and future studies 
are aimed toward evaluating potential utility o f such 
xylosides in treating myocardial infarction as well as 
cancer-associated thrombotic complications.
Keywords Proteoglycans • Glycosaminoglycans ■
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BLMVEC Bovine Lung Endothelial vascular Cell
4T1 Mouse Breast Cancer Cell
Introduction
Proteoglycans (PGj consist o f a core protein and one or 
more GAG chains. There are four major classes o f sulfoted 
GAG chains: heparan sulfate (HS), chondroitin sulfate 
(CS), dermatan sulfate (DS) and keratan sulfate. GAG side 
chains o f PGs play an important role in various cardiovas­
cular functions including haemostasis and thrombosis [1 ]. 
HS chains that contain a specific pentasaccharide sequence 
function as an endogenous anticoagulant through inhibition 
of factor Xa by activating anti-thrombin III (ATIII) [2^-]. 
One o f the main causes o f myocardial infarction (MI), a 
devastating disease that kills several million people world-
&  Springer
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wide annually, is the formation o f thrombi inside the coronary 
artery through platelet activation/aggregation. GAG side 
chains also play a  major role in various cancer processes. 
Dramatic changes in the expression o f biosynthetic and 
catabolic enzymes are attributed to alterations in GAG fine 
structures, which are suggested to affect tumor cell growth, 
invasion and metastasis [5, 6 ], For example, heparanase, a 
p-endoglucuronidase which is over expressed in a variety 
of malignant tumors, cleaves HS chains into smaller 
biologically active oligosaccharides that promote cancer 
growth, angiogenesis, tumor-cell invasion and migration 
[7-9], Melanoma associated CS and DS chains have been 
shown to stimulate tumor cell proliferation [1 0 ], while these 
GAG chains have been shown to surprisingly suppress 
angiogenesis [1 1 ].
Heparin, structurally similar to HS, has been in use as a 
major anticoagulant, for seven decades because o f  its 
abundance, cost, and potency. It is used as a blood thinner 
in surgical procedures and in tackling thrombotic compli­
cations associated with various cardiovascular and cerebro­
vascular dysfunctions. Heparin is also known to affect, 
tumor biology in a variety o f ways [11-13]. It decreases 
thrombin generation and fibrin formation, inhibits hepar­
anase, modulates P-selectin-vascular wall interactions and 
adhesion. A  chem ically m odified non-anticoagulant, 
heparin-like molecule is shown to reduce metastasis by 
more than 50% [11]. In various clinical trials, low 
molecular weight, heparin is shown to increase survival rate 
among patients with advanced malignancy.
Several animal derived GAGs and their derivatives have 
been in use as therapeutics to tackle thrombosis, M I and 
cancer. However, direct administration o f these GAG 
chains faces the problem o f molecular heterogeneity, 
possible contamination with pathogens or intentional 
chemical adulteration as evidenced in the latest, tragic 
episode o f heparin contamination [14, 15], Furthermore, it 
is administered intravenously, which makes it is less 
attractive for those who require prolonged prophylactic 
treatment. An alternative approach would be the use of 
xylosides to induce endogenous GAG chain biosynthesis 
without a core protein at. specific sites. Xylosides containing a 
hydrophobic aglycone can compete with endogenous core 
protein acceptor sites for assembly o f GAG chains in the 
Golgi apparatus [16-22], The hydrophobic aglycone helps 
xylosides pass through the membrane and hence increases 
priming activity/production o f GAG chains and its oral 
bioavailability. Interestingly, the composition o f primed 
GAG chains depends on the structure o f the aglycone moiety 
[23-25],
Arginine-glycine-aspaitate (RGD) selectively binds to 
(Xvpj integrin, which is abundantly expressed on the surface 
of many tumor cell types and activated endothelial cells 
surrounding cancer and myocardial infarction. Linear and
Springer
cyclic peptide sequences containing RGD motifs have been 
employed as targeting vectors for selective delivery of 
therapeutic and diagnostic agents by conjugating them to 
RGD sequences [26-30]. Moreover, RGD derivatives are 
also shown to interact selectively with the GPIIb/IHa receptor 
and therefore inhibit platelet aggregation [31]. Therefore, 
RGD-conjugated xylosides are predicted to have a dual use 
as anticoagulants as well as anti-platelet agents in tackling 
thrombotic complications associated with MI, cancer and 
other disease conditions. Here, we describe the synthesis o f 
RGD— conjugated xylosides using click-chemistry and 
report on their GAG priming activity in a variety o f cellular 
systems.
Chinese hamster ovary (CHO) cell line, pgsA-745, which is 
defective in xylosyl transferase, was obtained from Amer­
ican Type Culture Collection. The cell culture reagents for 
CHO cell line were obtained from HyClone. Bovine lung 
microvascular endothelial cell (BLMVECJ and Mouse 
breast cancer cells (4T1) were gifts from Dr Randall Dull 
and Dr David Bull, University o f Utah, respectively. The 
cell culture reagents for BLMVEC and 4T1 (MCDB-131 
complete) were obtained from Vec Technologies. Na2 3 :,S0 4  
was purchased from MP Biochemicals and Ultima-FloAP 
scintillation cocktail for flow scintillation analysis was 
obtained from PerkinElm er Life Sciences. All other 
chemicals and biochemicals were obtained from Sigma. 
Linear RGD peptide 4 was synthesized using peptide 
synthesizer available through core facilities at the Univer­
sity of Utah, and cyclic RGD peptide 7 was purchased from 
Peptides International Inc. The DEAE-Sepharose gel was 
purchased from Amersham Biosciences. The anion- 
exchange chromatography column TSK-GEL DEAE-3SW 
(7.4 mm * 7.5 cm, 10 p n  particle size) and the size 
ex c lu s io n  ch ro m ato g rap h y  co lum ns G 3000SW X L  
(7.8 m m * 30 cm) were obtained from Tosoh Bioscience.
Anhydrous solvents were purchased and used directly or 
dried over standard drying agents and freshly distilled prior 
to use. Reactions were monitored by TLC on silica gel 60 
F2 5 4  with detection by Von’s reagent. Intermediate com­
pounds were purified by flash chromatography columns 
using silica gel 60 (230^4-00 mesh) and were run under 
pressure at 5 -7  psi. Final products were purified by high 
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phase C l 8  column (VYDAC 2.2 cm* 25 cm) with solvent 
A (25 mM formic acid in water) and solvent B (95% 
acetonitrile) at a flow rate of 5 ml/min in a linear gradient 
over 120 min starting with 0% B. All synthetic compounds 
were characterized by mercury 400 MHz spectrometry. Hie 
compounds were also confirmed for their final structures 
using a  Finnigan LCQ mass spectrometry in either positive 
or negative ion mode.
2,3,4-Tri-0-Acetyl-/3-Z)-xylopyranosyl azide (1): Trime- 
thylsilyl azide (1.5 mmol) and SnCU (0.5 mmol) were 
added dropwise to a stirred solution o f fully acetylated 
xylose derivative ( 1  mmol) m dry u±i2 u i2, and stirring was 
continued at room temperature. The progress of the reaction 
was checked by TLC, and after the completion of the 
reaction, the reaction mixture was then evaporated under 
vacuum to give a residue that was further purified by low 
pressure flash silica column chromatography to yield the 
compound 1 [32],
iV-(2,3,4-tri-0-acetyl-/3-.D-xylopyranosyl) chloroaceta- 
mide (2): 2,3,4-Tri-0-Acetyl-/3-.D-xylopyranosyl azide 1) 
(1 mmol) was dissolved in dry CH2 C12  (20 ml). The 
mixture was cooled at 0°C. Chloroacetic anhydride 
( 1  mmol) was added to the solution, followed by tri­
phenyl phosphine ( 1  mmol), and the reaction was continued 
overnight. After the reaction was complete, the solvent was 
removed using rotary evaporator under reduced pressure. 
The reaction mixture was extracted using ethyl acetate and 
water. The organic layer was washed with saturated brine 
solution and evaporated under vacuum to give a residue, 
which was purified by silica column chromatography to 
give the title compound 2 [33],
iV-(2,3,4-tri-0-acetyl-/3-xylopyranosyl) azidoacetamide 
(3): iV-(2,3,4-tri-0-acetyl-/3-D-xylopyranosyl) chloroaceta- 
mide 2) (1 mmol) was taken in a 100 ml RB flask and dry 
DMF (20 ml) was added, followed by the addition of 
sodium azide (2 mmol). The reaction mixture was heated to 
90°C under stirring. Progress o f the reaction was monitored 
by TLC using ethyl acetate and hexane (1:1) as the eluant. 
After the reaction was complete, the reaction mixture was 
cooled and diluted with ethyl acetate. The organic layer was 
washed with water, dried over sodium sulfate and concen­
trated to obtain a syrupy materials that was further purified 
by silica flash column chromatography to give the title 
compound 3 [34],
Propargylated cyclic RGD (8 ): Propiolic acid (10 mmol) 
was taken in a RB flask and dry DMF (20 ml) was added,
followed by addition o f hydroxybenzotriazole (5 mmol) 
and 1, 3-dispropylcarbodimide (5 mmol). The reaction 
mixture was stirred for 1 h  before cyclic RGD (1 mmol) 
was added, and stirred for another hour. The reaction mixture 
was evapoiated using a rotary evaporator under reduced 
pressure. The reaction mixture was purified by HPLC-reverse 
phase Cl 8  column with solvent A  (25 mM formic acid in 
water) and solvent B (95% acetonitrile) in a linear gradient 
stating with 0% B to give the pure compound 8 .
Preparation o f RGD-conjugated xylosides (5, 6 and 9): 
To a solution o f alkyne group containing linear or cyclic 
K(jU derivative ( 1  mmol) and xylosyl azide derivative 
(1 mmol) in DMF ( 8  ml) / water (2.6 ml ) mixture, sodium 
ascorbate (0.8 mmol) was added, followed by Cu2 S 0 4.5 
H20 (0.4 mmol) at room temperature and the mixture was 
stilled until the disappearance o f the starting materials as 
indicated by TLC. A t the end o f the reaction, the reaction 
mixture was concentrated using the rotary evaporator under 
reduced pressure. The reaction mixture was purified by 
HPLC— reverse phase C l 8  column with solvent A  (25 mM 
formic acid in water) and solvent B (95% acetonitrile) to 
give the final compounds, 5, 6 & 9. Compound 5: 'H  NMR 
(CD3 OD): 5 8.07 (s, 1H), 5.97 (d, J=8.98 Hz, 1H), 5.55­
5.44 (m, 2H), 5.20-5.14 (m, 1H), 4.58 (t, J=4.68 Hz, 1H), 
4.46 (dd, J=15.62 Hz, 24.80 Hz, 2H), 4.41-1.36 (m, 1H), 
4.22 (dd, J=5.47 Hz, 11.33 Hz, 1H), 4.02 (d, J=17.18 Hz, 
1H), 3.74 (t, J=  10.54 Hz, 1H), 3.72 (d, 1=16.79 Hz, 1H), 
3.26-3.20 (m, 1H), 3.12-3.05 (m, 1H), 2.92 (dd, J=4.3 Hz, 
16.60 Hz, 1H), 2.53 (dd, J=5.08 Hz, 16.40 Hz, 1H ), 2.04 
(s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.82 (s, 3H), 1.70-1.64 
(m, 2H); MS (ESf): calcd for C2 SH 4 3 N 1 0 O 1 3  [M +H]+ 
727.2932; found 727.3333. Compound 6 : 'H  NM R 
(CD3 OD): 5 7.86 (s, 1H), 5.28 (t, J-9 .3 7  Hz, 1H), 5.20 
(d, J=8.98 Hz, 1H), 5.12 (d, 1=1.95 Hz, 1H), 4.58-1.57 
(m, 1H), 4.53 (s, 1H), 4.44 (s, 1H), 4.40-1.35 (m, 1H), 
4.06-1.02 (m, 1H), 3.98 (s, 1H), 3.72 (d, J= 16.79 Hz, 1H), 
3.48 (t, J=11.13 Hz, 1H), 3.25-3.22 (m, 1H), 3.13-3.08 (m, 
1H), 2.92 (dd, J=4.3 Hz, 16.4 Hz, 1H), 2.50 (dd, J= 
4.69 Hz, 16.60 Hz, 1H), 2.06-1.96 (m, 12 H), 1.68-1.63 
(m, 2H) ; MS (ESI): calcd for C jo H ^ N u O ^  [M +H]+ 
784.3226; found 784.3400. Compound 9: *H NM R 
(CD3OD): 5 8.65 (s, 1H), 8.60 (s, 1H), 8.34 (s, 1H), 7.86 
(d, J=6.64 Hz, 1H), 7.54 (t, J=7.81 Hz, 1H), 7.25-7.16 (m, 
3H), 6.09 (d, J=8.98 Hz, 1H), 5.62-5.56 (m, 1H), 5.50 (t, J= 
8.98 Hz, 1H), 5.24—5.18 (m, 1H), 4.66 (t, J=5.08 Hz, 1H), 
4.54 (t, J=6.64 Hz, 1H), 4.41 (t, J=6.64 Hz, 1H), 4.30-1.24
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Scheme 1 Synthesis of jV-(2,3,4-tri-0-acetyl-/?-xylopyranosyl) azidoacetamide: Ph3P, triphenyl phosphine; dichloromethane; NaN3,
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495 i^L Ham’s/F12 containing 10% dialyzed FBS. A solution 
containing a specific primer at 100X the final concentration 
was prepared. 5 [iL of appropriate 100X primer was added to 
various wells to yield the appropriate concentration and 
50 [iCi o fN a 2 3 5 S 0 4  was also added to each well as tracer. 
The 24-well plates were incubated at 37°C in a humidified 
incubator (5% C 0 2) for 24 h.
Purification and quantitation of GAG chains: The entire 
contents o f the wells were transferred to a microcentrifuge 
tube and subjected to centrifugation at 16000 x  g for 5 min. 
The supernatant was transferred to a fresh tube and 0.016% 
Triton X-100 (1.5 volumes) was added. The diluted 
supernatant was loaded on a 0.2 ml DEAE-sepharose column 
pre-equilibrated with 2 ml of wash buffer (20 mM NaOAc, 
0.1 M  NaCl and 0.01%TritonX-100, pH 6.0) and the column 
was washed with 6  ml of wash buffer. The bound HS/CS was 
eluted using 1.2 ml o f  elution buffer (20 mM NaOAc and 1 M 
NaCl, pH 6.0). The priming activities o f xylosides 5, 6  & 9 
were evaluated by quantitating the 3 5 S-radioactivity incorpo­
rated in to the purified HS/CS chains by liquid scintillation 
counter.
Sulfate density analysis o f GAG chains: The purified 
GAG chains were analyzed by HPLC coupled to an inline 
radiomatic detector. Xyloside primed GAG chains o f  equal 
quantity were diluted five-fold with HPLC solvent A 
(10 mM KH 2 P 0 4, pH  6.0, 0.2% CHAPS) for anion 
exchange chromatography analysis. The sample was loaded 
on a HPLC-DEAE column and eluted from the column 
with a linear gradient o f 0.2 M  1 M  NaCl over 80 min at a 
flow rate o f 1 ml/min. The radioactive GAG chains were 
detected by radiometric flo-one A505A detector. The HPLC 
effluent was mixed w ith Ultima-Flo A P scintillation 
cocktail in a 2 : 1  ratio and detected in the flow scintillation
Chain length analysis o f GAG chains primed by RGD- 























Fig. 1 Priming activity of two Linear RGD-xylosides using pgs A-745 
cell lines at various concentrations. CHO cells were treated with Linear 
RGD xylosides 5 and 6 at 10, 30, 100 and 300 (iM in the presence of 
Nl-.;.'1’SO4 (50 aCi) as described in the experimental section. The 
GAG chains were purified by anion exchange chromatography and 
quantitated using liquid scintiLLation counter. The data shown is 
average of two independent experiments
Fig. 2 a GAG chains primed by xyloside 5 in pgsA-745 cell lines 
were analyzed using anion exchange HPLC: The bound GAG chains 
were eluted with a linear gradient of 0.2 M to 1 M NaCL over SO min 
at a flow rate of 1 ml/min. The elution profiles of GAG chains, primed 
at 100 |iM (gi'ey) and 300 (black), are shown, b Hie sizes of GAG 
chains primed by xyloside S in pgsA-745 cells were analyzed by size 
exclusion HPLC: the GAG chains, fractionated on two tandem 3000 
SWLX columns, were eLuted with an isocratic gradient of phosphate 
buffer for 90 min at a flow rate of 0.5 ml/min as described in the 
experimental section. The elution profiles of the GAG chains primed 
at 100 {grey trace) and 300 (black trace) are shown. V0 and 
Vt represent void and total volume, respectively. These elution profiles 
are representative of two independent experiments
by various RGD-xyloside conjugates was determined by 
measuring migration time on a size exclusion column using 
a HPLC with inline radiodetector. The GAG chains were 
loaded on to two tandem G3000SWLX columns (Tosoh, 
7.8 m m x30 cm) and analyzed with the aid of an inline 
radiodetector using phosphate buffer (100 mM KH 2 P 0 4, 
100 mM NaCl, pH  6 ) as eluant. The average molecular 
weight was determined by measuring the migration time of 
the GAG chains in comparison to those o f polystyrene 
sulfonate standards performed under similar conditions.
Results and  discussion
Synthesis o f  RGD-xylosides
In recent years, there has been great interest in assembling a 
number o f biologically active carbohydrate conjugates 
using click chemistry because o f its mild reaction con-






Fig. 3 a Anion exchange chromatography analysis of GAG chains 
produced by xyloside 9 in pgsA-745 cell lines: Purified GAG chains 
(grey trace for control cells and black trace for cells treated with 
100 .:M xyloside 9) were analyzed using HPLC-DEAE anion 
exchange drromalugrapliy using a linear gradient o f  0.2 M  lo 1 M 
NaCl as an eluant over 80 min at a flow rate of 1 ml/min. b Size 
exclusion profiles of GAG chains produced by xyloside 9 in pgsA-745 
cell line: GAG chains were fractionated using two 3000 SWLX SEC 
columns that were connected in tandem using an isocratic gradient of 
phosphate buffer for 90 min at a flow rate of 0.5 ml/min as described 
in the experimental section (grey trace for control cells and black trace 
for cells treated with 100 ;i\l  xyloside 9). V D and Vt represent void 
and total volume, respectively. These elution profiles are representa­
tive of two independent experiments
ditions, the generation o f regioselective molecules with 
high efficiency in water and compatibility with most 
functional groups in biological systems [35-37]. This 
bioconjugation approach relies on the Cu(I)-catalyzed 
orthogonal reaction o f azide containing xylosyl scaffold 
w ith terminal alkyne containing RGD m otifs in the 
presence of other reactive functional groups. Furthermore, 
this approach offers two advantages: a) the 1 ,2 , 3-triazole 
ring generated during the click-chemistry is a metabolically 
stable linker between xylose residue and RGD peptide; bj 
the triazole ring can facilitate hydrogen-bonding interac­
tions resulting in favorable and productive biological 
effects.
Xylosyl azide 1 was converted into 3 by first converting 
the azide group into the chloroacetamide followed by the 
replacement o f the chloride group with an azide as shown
Springer





Fig. 4 a GAG chains, primed by xyloside S in endothelial cell line, 
were analyzed using anion exchange HPLC. The bound GAG chains 
were eluted with a linear gradient of 0.2 M to 1 M NaCl over 80 min 
at a flow rate of 1 ml/min. The radiodetector trace of the GAG chains 
isolated from control cells [grey trace) and cells treated with 100 nM 
xyloside (black trace) are shown, b GAG chains, primed by xyloside 
S in endothelial cell line, were analyzed using two SEC (3000 SWLX) 
that were connected in tandem and were eluted with an isocratic 
gradient of phosphate buffer for 90 min at a flow rate of 0.5 ml/min as 
described in the experimental section. The elution profile of the GAG 
chains, primed by xyloside 5 at 100 .:M (black trace; control as grey 
trace), is shown. V0 and Vt represent void and total volume, 
respectively. These elution profiles are representative of two indepen­
dent experiments
in Scheme 1. These two xylosyl derivatives, 1 & 3, contain 
reactive azide group for orthogonal coupling with RGD 
peptides containing terminal alkyne group in the subse­
quent steps. RGD peptides, 4 and 7, were purchased from 
commercial sources. These RGD peptides were coupled 
with propargyl amine using well established coupling 
procedure. In a  similar manner, cyclic RGD peptide 7 
containing side chain amine group was reacted with 
propargylic acid under similar conditions to obtain prop- 
argylated cyclic RGD peptide 8 in high yield as shown in 
Scheme 3. After preparing appropriate orthogonally func- 
tionalized RGD peptides and xylosides, we turned to 
assembling RGD-conjugated xylosides, 5, 6  and 9, using 
click-chemistry as described in Schemes 2 and 3. The final 
products were purified on reverse phase C l 8  column using 
HPLC as described in the experimental section.
102
Glycoconj J (2010) 27:625-633 631
Priming activity o f RGD-xylosides in CHO cells
The very first step in the biosynthesis o f proteoglycans is 
the xylosylation of certain serine residues o f the core 
protein [38], Following xylosylation o f the core protein, a 
tetrasaccharide linkage region, which serves as an acceptor 
site for elongation o f GAG chains, is assembled [39-42]. It 
has been known for over three decades that GAG chains 
can also be assembled on xylosides without a core protein 
provided xylosides carry hydrophobic aglycone [2 0 , 2 2 ], 
We have synthesized various click-xylosides with hydro­
phobic moiety and demonstrated their ability to induce 
GAG chains in a cellular system [23]. A  mutant Chinese 
hamster ovary [CHO] cell line, pgsA-745, is a convenient 
cellular system for determining the priming activity of 
exogenously supplied RGD-conjugated xylosides, because 
this cell line lacks active xylosyltransferase enzyme and 
therefore does not make endogenous GAG chains [43], 
Thus, it is easier to determine whether RGD-conjugated 
xylosides induce GAG chains using this cell line. RGD- 
conjugated xylosides were screened in cell culture at 
various concentrations (10, 30, 100 and 300 |xM). We 
found that the nature of linkage between xylose and RGD 
can affect the priming activity (Fig. 1). The results from 
priming activity analysis suggest that RGD-xyloside 5 is a 
better GAG primer than RGD-xyloside 6  at 100 |xM and 
300 (tM. Therefore, the GAG chains primed by xyloside 5 
were further analyzed for their sulfation pattern by DEAE- 
anion exchange HPLC column and for their molecular 
weights using size exclusion columns as outlined in the 
experimental section. It. is interesting to note that the extent, 
o f sulfation o f GAG chains primed by xylosides at 100 |iM 
m d  300 |xM are nearly identical suggesting that these 
concentrations are optimal for GAG induction without 
challenging the Golgi machinery (Fig. 2). Nevertheless, 
Xyloside 5 primed nearly three times more GAG chains at 
300 (iM compare to 100 [iM in CHO cells. The chain 
length o f GAG chains primed by xyloside 5 in CHO cells 
was determined by measuring migration time o f GAG 
chains in comparison to those o f polystyrene sulfonate 
standards performed under similar conditions on size 
exclusion analyses and suggests that GAG chains, primed 
by xyloside 5 in CHO cells, have an average molecular 
weight o f 45 KDa at 100 (iM and 19 KDa at 300 |iM 
concentration.
Cyclic RGD peptides are shown to bind more selectively 
than their linear motifs to tXvp3  integrin expressing 
activated endothelial cells and cancer cell lines [28, 44, 
45]. Therefore, we synthesized xyloside conjugated to 
cyclic-RG D  peptide m o tif 8 ) using click-chem istry 
(Scheme 3). It. is interesting to note that xyloside 9 primed 
GAG chains whose average molecular weight is higher than 
those primed by xyloside 5 in CHO cells. Xyloside 9
primed GAG chains migrated between 20-28 min in size 
exclusion colum n w ith average molecular weight o f 
67 KDa in comparison to those o f polystyrene sulfonate 
standard (Fig. 3). GAG chains primed by xylosides 5 and 9 
were digested with heparin lyases I, II and III to determine 
HS/CS composition. It is interesting to note that, xyloside 5 
primed about 50% HS chains, whereas Xylsoide 9 primed 
about 25% HS chains. Xyloside 6 , on the other hand, 
primed about 80% HS chains even though this scaffold lias 
lower priming activity than Xyloside 5.
a vp 3  integrin receptors are elevated in activated endothelial 
cells, angiogenic cardiomyocytes and highly vascularized
Fig. S a GAG chains primed by xyloside S in cancer cell line were 
analyzed using anion exchange HPLC. The bound GAG chains were 
eluted with a linear salt, gradient for 80 min as described in the 
experimental section. The radiodetector trace of the eluted GAG 
chains from control cells (grey trace) and cells treated with 100 [:M 
xyloside (black trace) are shown, b GAG chains primed by xyloside S 
in 4T1 cell line were analyzed using SEC column as described in the 
experimental section, were eluted with an isocratic gradient of 
phosphate buffer for 90 min at a flow rate of 0.5 ml/min. The 
radiodetector traces of the eluted GAG chains, primed by xyloside S at 
100 .lM (black trace) and control cells (grey trace), are shown. These 
elution profiles shown here are representative of two independent 
experiments
Priming activity o f xylosides in endothelial cells 
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cancer cells, and therefore, RGD-conjugated xylosides are 
expected to be up taken by these cells* For these reasons, 
we chose to determine the priming activity o f  RGD- 
conjugated xylosides in  endothelial cells (BLMVEC) and 
mouse breast cancer cell line (4T1). The priming activity o f 
RGD xylosides in endothelial cells and cancer cells are 
determined as described earlier for CHO cells. The xyloside 
5 did prime on both endothelial cells and cancer cells 
(Figs* 4 and 5). Xyloside 5 was able to  induce GAG chains 
by 6-fold in endothelial cells and 3-fold in cancer cell line. 
Molecular weight o f  GAG chains primed by xyloside 5 was 
round to b e - lu  KDa m the endothelial cell and cancer cell 
line. It was disappointing to note that cyclic-RGD conju­
gated xyloside 9 was unable to prime GAG chains in either 
the endothelial cells or cancer cell line. It is possible that 
the cyclic-RGD m otif may prevent the selective transport o f 
xyloside to the Golgi machinery, where they prime GAG 
chains. Alternatively, cyclic m otif m ay sterically interfere 
with biosynthetic enzymes preventing the priming o f GAG 
chains by xyloside 9. For these reasons, w e plan to make a 
library o f  cyclic-RGD m otifs w ith variable distance 
between the xylose and the peptide with an aim to discover 
new scaffolds that prime GAG chains.
In summary, we have successfully synthesized RGD- 
conjugated xylosides that target cells displaying the 0 Cvp3 
integrin using click chemistry. These RGD-conjugated hom­
ing xylosides are able to prime GAG chains in various cellular 
systems indicating their likely applications in tackling MI, 
thrombosis and cancer associated vascular complications, 
where GAG chains are known to modulate various patholog­
ical processes. Future studies will focus on the synthesis o f 
additional homing xylosides and evaluation of their pharma­
cokinetics and pharmacodynamics in various animal models.
Acknowledgment This work was supported by NIH (GM075168) 
and Human Frontier Science Program grants to BK.
References
1. Cummings, R.D.: The repertoire of glycan determinants in the 
human glycome. Mol. Biosyst. 5, 1087-1104 (2009)
2. Damus, P.S., Hicks, M., Rosenberg, R.D.: Anticoagulant action of 
heparin. Nature. 246, 355-357 (1973)
3. Hopwood, J., Hook, M., Linker, A., Lindahl, U.: Anticoagulant 
activity of heparin: isolation of antithrombm-binding sites. FEBS 
Lett. 69, 51-54 (1976)
4. Kuberan, B., Lech, M.Z., Beeler, D.L., Wu, Z.L., Rosenberg, R  
D.: Enzymatic synthesis of antithrombin Ill-binding heparan 
sulfate pentasaccharide. Nat. Biotechnol. 21, 1343-1346 (2003)
5. Sasisekharan, R., Shriver, Z., Venkataraman, G., Naray anas ami, 
U.: Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. 
Rev. Cancer. 2, 521-528 (2002)
6 . Raman, K., Kuberan, B.: Chemical tumor biology of heparan 
sulfate proteoglycans. Curr. Chem. Biol. 4, 20-31 (2010)
7. Purushothaman, A., Chen, L., Yang, Y., Sanderson, R.D.: 
Heparanase stimulation of protease expression implicates it as a
Springer
master regulator of the aggressive tumor phenotype in myeloma. 
J. Biol. Chem. 283, 32628-32636 (2008)
8. Fux, L., Ilan, N., Sanderson* R.D., Vlodavsky, I.: Heparanase: 
busy at the cell surface. Trends Biochem. Sci. 34, 511-519 (2009)
9. Vlodavsky, I., Ilan, N., Nadir, Y., Brenner, B., Katz, B.Z., Naggi, 
A., Torri, G., Casu, B., Sasisekharan, R.: Heparanase, heparin and 
the coagulation system in cancer progression. Thromb. Res. 120 
(Suppl. 2), SI 12-120 (2007)
10. Yang, J., Price, M.A., Neudauer, C.L., Wilson, C., Ferrone, S., 
Xia, H., Iida, J., Simpson, M.A., McCarthy, J.B.: Melanoma 
chondroitin sulfate proteoglycan enhances FAK and ERIC activa- 
tionby distinct mechanisms. J. Cell Biol. 165, 881-891 (2004)
11. Yip, G.W., Smollich, M., Gotte, M.: Therapeutic value of 
glycosaminoglycans in cancer. Mol. Cancer Ther. 5, 2139-2148 
(2006)
12. Varki, N.M., Varki, A.: Heparin inhibition of selectin-mediated 
interactions during the hematogenous phase of carcinoma metas­
tasis: rationale for clinical studies in humans. Semin. Thromb. 
Hemost. 28, 53-66 (2002)
13. Borsig, L., Wong, R., Feramisco, J., Nadeau, D.R., Varki, N.M., 
Varki, A.: Heparin and cancer revisited: mechanistic connections 
involving platelets, P-selectin, carcinoma mucins, and tumor 
metastasis. Proc. Natl. Acad. Sci. U. S. A. 98, 3352-3357 (2001)
14. Kishimoto, T.K., Viswanathan, K., Ganguly, T., Elankumaran, S., 
Smith, S., Pelzer, K., Lansing, J.C., Sriranganathan, N., Zhao, G., 
Galcheva-Gargova, Z., Al-Hakim, A., Bailey, G.S., Fraser, B., 
Roy, S., Rogers-Cotrone, T., Buhse, L., Whary, M., Fox, J., Nasr, 
M., Dal Pan, G.J., Shriver, Z., Langer, R.S., Venkataraman, G., 
Austen, K.F., Woodcock, J., Sasisekharan, R.: Contaminated 
heparin associated with adverse clinical events and activation of 
the contact system. N. Engl. J. Med. 358, 2457-2467 (2008)
15. Blossom, D.B., Kallen, A.J., Patel, P.R., Elward, A., Robinson, L., 
Gao, G., Langer, R., Perkins, K.M., Jaeger, J.L., Kurkjian, K.M., 
Jones, M., Schillie, S.F., Shehab, N., Ketterer, D., Venkataraman,
G., Kishimoto, T.K., Shriver, Z., McMahon, A.W., Austen, K.F., 
Kozlowski, S., Srinivasan, A., Turabelidze, G., Gould, C.V, 
Arduino, M.J., Sasisekharan, R.: Outbreak of adverse reactions 
associated with contaminated heparin. N. Engl. J. Med. 359, 
2674-2684 (2008)
16. Gibson, K.D., Segen, B.J., Audhya, T.K.: The effect of beta-D- 
xylosides on chondroitin sulphate biosynthesis in embryonic 
chicken cartilage in the absence of protein synthesis inhibitors. 
Biochem. J. 162, 217-233 (1977)
17. Schwartz, N.B., Ho, P.L., Dorfman, A.: Effect of beta-xylosides 
on synthesis of cartilage-specific proteoglycan in chondrocyte 
cultures. Biochem. Biophys. Res. Commun. 71, 851-856 (1976)
18. Robinson* H.C., Brett, M.J., Traiaggan, P.J., Lowther, D.A., 
Okayama, M.: The effect of D-xylose, beta-D-xylosides and 
beta-D-galactosides on chondroitin sulphate biosynthesis in 
embryonic chicken cartilage. Biochem. J. 148, 25-34 (1975)
19. Galligani, L., Hopwood, J., Schwartz, N.B., Dorfman, A.: 
Stimulation of synthesis of free chondroitin sulfate chains by 
beta-D-xylosides in cultured cells. J. Biol. Chem. 250, 5400-5406 
(1975)
20. Schwartz, N.B., Galligani, L., Ho, P.L., Dorfman, A.: Stimulation 
of synthesis of free chondroitin sulfate chains by beta-D-xylosides 
in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 71, 4047-4051 
(1974)
21. Abrahamsson, C.O., Ellervik, U., Eriksson-Bajtner, J., Jacobsson, 
M., Mani, K.: Xylosylated naphthoic acid-amino acid conjugates 
for investigation of glycosaminoglycan priming. Carbohydr. Res. 
343, 1473-1477 (2008) ........................
22. Okayama, M., Kimata, K., Suzuki, S.: The influence of p- 
nitrophenyl beta-d-xyloside on the synthesis of proteochondroitin 
sulfate by slices of embryonic chick cartilage. J. Biochem. 74, 
1069-1073 (1973)
104
Glycoconj J (2010) 27:625-633
23. Kuberan, B., Ethirajan, M., Victor, X.V., Tran, V., Nguyen, K., 
Do, A.: “Click” xylosides initiate glycosaminoglycan biosynthesis 
in a mammalian cell line. Chembiochem. 9, 198-200 (2008)
24. Fritz, T.A., Lugemwa, F.N., Sarkar, A.K., Esko, J.D.: Biosynthesis 
of heparan sulfate on beta-D-xylosides depends on aglycone 
structure. J. Biol. Chem. 269, 300-307 (1994)
25. Victor, X.V., Nguyen, T.K., Ethirajan, M., Tran, VM., Nguyen, K. 
V, Kuberan, B.: Investigating the elusive mechanism of glycos­
aminoglycan biosynthesis. J. Biol. Chem. 284, 25842-25853 
(2009)
26. DeNardo, S.J., Burke, P.A., Leigh, B .R, O’Donnell, R.T., Miers, 
L.A., Kroger, L.A., Goodman, S.L., Matzku, S., Jonczyk, A., 
Lambom, K.R., DeNardo, G.L.: Neovascular targeting with cyclic 
RGD peptide (cRGDf-ACHA) to enhance delivery of radio­
immunotherapy. Cancer Biother. Radiopharm. 15, 71-79 (2000)
27. Meyer, A., Auemheimer, J., Modlinger, A., Kessler, H.: Targeting 
RGD recognizing integrins: drug development, biomaterial re­
search, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723­
2747 (2006)
28. Park, K., Kim, Y.S., Lee, G.Y., Park, R.W., Kim, I.S., Kim, S.Y., 
Byun, Y.: Tumor endothelial cell targeted cyclic RGD-modified 
heparin derivative: inhibition of angiogenesis and tumor growth. 
Pharm. Res. 25, 2786-2798 (2008)
29. Carlson, C.B., Mowery, P., Owen, R.M., Dykhuizen, E.C., 
Kiessling, L.L.: Selective tumor cell targeting using low-affinity, 
multivalent interactions. ACS Chem. Biol. 2, 119-127 (2007)
30. Owen, R.M., Carlson, C.B., Xu, J., Mowery, P., Fasella, E., 
Kiessling, L.L.: Bifunctional ligands that target cells displaying 
the alpha v beta3 integrin. Chembiochem. 8, 68-82 (2007)
31. Wang, W., Borchardt, R.T., Wang, B : Orally active peptidomi- 
metic RGD analogs that are glycoprotein Ilb/lIIa antagonists. 
Curr. Med. Chem. 7, 437-453 (2000)
32. Gyorgydeak, Z., Szilagyi, L., Paulsen, H.: Synthesis, structure, and 
reactions of glycosyl azide. J. Carbohydr. Chem. 12, 139-163 (1993)
33. Inazu, T., Kobayashi, K.: A new method for the synthesis of NK- 
Fmoc-N13-glycosylated-L-asparagine derivatives. Synlett. 869­
870 (1993)
34. Aich, U., Loganathan, D.: Synthesis of N-(beta-glycopyranosyl) 
azidoacetamides. J. Carbohydr. Chem. 24, 1-12 (2005)
35. Tomoe, C.W., Christensen, C., Meldal, M.: Peptidotriazoles on 
solid phase: [1, 2 , 3]-triazoles by regiospecific copper(i)-catalyzed
633
1, 3-dipolar cycloadditions of terminal alkynes to azides. J. Org. 
Chem. 67, 3057-3064 (2002)
36. Meldal, M., Tomoe, C.W.: Cu-catalyzed azide-alkyne cycloaddition. 
Chem. Rev. 108, 2952-3015 (2008)
37. Bertozzi, C.R., Kiessling, L.L.: Chemical glycobiology. Science. 
291, 2357-2364 (2001)
38. Lindahl, U., Roden, L.: The role of galactose and xylose in the 
linkage of heparin to protein. J. Biol. Chem. 240, 2821-2826 
(1965)
39. Sugahara, K.: The carbohydrate-protein linkage region of proteo­
glycans and glycosaminoglycan biosynthesis. Seikagaku. 61, 
496-500 (1989)
40. Kitagawa, H., Oyama, M., Masayama, K., Yamaguchi, Y., Sugahara, 
K.: Structural variations in the glycosaminoglycan-protein linkage 
region of recombinant decorin expressed in Chinese hamster ovary 
cells. Glycobiology. 7, 1175-1180 (1997)
41. Kitagawa, H., Tone, Y., Tamura, J., Neumann, K.W., Ogawa, T., 
Oka, S., Kawasaki, T., Sugahara, K.: Molecular cloning and 
expression of glucuronyltransferase I involved in the biosynthesis 
of the glycosaminoglycan-protein linkage region of proteoglycans. 
J. Biol. Chem. 273, 6615-6618 (1998)
42. Gulberti, S., Lattard, V., Fondeur, M., Jacquinet, J.C., Mulliert, G., 
Netter, P , Magdalou, J., Ouzzine, M., Foumel-Gigleux, S.: Phos­
phorylation and sulfation of oligosaccharide substrates critically 
influence the activity of human betal, 4-galactosyltransferase 7 
(GalT-I) and betal, 3-glucuronosyltransferaseI (GlcAT-I) involved in 
the biosynthesis of the glycosaminoglycan-protein linkage region of 
proteoglycans. J. Biol. Chem. 280, 1417-1425 (2005)
43. Esko, J.D., Stewart, T.E., Taylor, W.H.: Animal cell mutants 
defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. 
Sci. U. S. A. 82, 3197-3201 (1985)
44. Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., 
Kessler, H., Timpl, R., Engel, J.: Selective recognition of cyclic 
RGD peptides of NMR defined conformation by alpha lib beta 3, 
alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269, 
20233-20238 (1994)
45. Kaufmann, D., Fiedler, A., Junger, A., Auemheimer, J., Kessler,
H., Weberskirch, R.: Chemical conjugation of linear and cyclic 
RGD moieties to a recombinant elastin-mimetic polypeptide—a 
versatile approach towards bioactive protein hydrogels. Macro- 
mol. Biosci. 8, 577-588 (2008)
Springer
CHAPTER 5
SYNTHESIS AND BIOLOGICAL EVALUATION OF 




PGs are the most ubiquitous glycoconjugates found on cell surfaces and in the 
extra cellular matrix (7). These highly charged, complex PGs regulate various 
molecular, cellular, pathological, and physiological events through binding to a wide 
array of proteins (2, 3). The distinct structural feature of all PGs, with the exception of 
decorin, is the substitution of a core protein with multiple GAG chains such as HS, CS, 
and/or DS (Figure 5.1) (7).
GAG attachment sites are highly conserved among various PGs in several 
mammals (4, 5). This implies that multiple GAG chains are required for optimal 
biological functionality of PGs in various species. Single GAG chains can perhaps not 
provide the same functionality that multiple GAG chains can. Only a few studies have 
examined the biological significance of GAG multivalency (4, 6 ). The cell surface PGs
Figure 5.1. Schematic representation of various cell surface and ECM-bound PGs
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from simple and stratified epithelium are shown to be polymorphic due mostly to 
variability in both the number of GAG chains attached to the core protein and GAG size 
(7). The variable chain valency is suggested to facilitate the distinct adhesive 
requirements of these two epithelial cell types.
Xylosylation of certain serine residues of the core proteins, a rate limiting first 
step in the assembly of PGs, is catalyzed by xylosyltransferases (8-70). It is known that 
xylosides can function as GAG chain initiators without a core protein provided that 
xylosides carry a hydrophobic group (77-75). We have earlier shown that click- 
xylosides prime a diverse array of GAG chains and suggested the presence of 
GAGOSOMEs, distinct macromolecular enzyme complexes that regulate the 
combinatorial biosynthesis of complex GAG chains (76, 77). Several earlier studies 
have rigorously utilized synthetic mono-xylosides to further our understanding of the 
role of endogenous PGs in model organisms and also to elucidate the elusive 
biosynthetic mechanism. Only one study has examined synthetic bis-xylosides, which 
carry two xylose residues per molecular scaffold, for their priming activity (78). These 
synthetic bis-xylosides carry very labile O-glycosidic linkage. Given the importance of 
multiple GAG chains for cooperative interactions with protein ligands and for optimal 
biological functions, there is a great deal of interest in synthesizing stable, small 
molecular scaffolds carrying a variable number of xylose residues for biological studies. 
Thus, synthetic cluster-xylosides should afford molecular scaffolds with multiple GAG 
chains mimicking endogenous PGs to define the role of GAG glycome and GAG 
multivalency in various developmental and physiological processes.
In the present study, “click chemistry” is utilized to assemble cluster-xylosides 
carrying one, two, three, or four xylose residues. The priming activity of these cluster-
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xylosides was investigated in a model cellular system, pgsA-745 cell line, lacking active 
xylosyltransferase (19). Furthermore, the distance between two xylose residues in a 
group of bis-xylosides and the number of xylose units in cluster-xylsodies were 
examined to affect the priming activity, the type of GAG chains primed, their sulfation 
pattern, and chain length. The results obtained in the present study provide further 
insights into the nature of assembly of multiple GAG chains on the synthetic scaffolds 
and suggest that these potential PG mimetics can be utilized to study the functional role 
of GAG chain valency in biological systems.
5.2. Results
5.2.1. Synthesis of Cluster-xylosides
Cluster-xylosides were hypothesized to carry multiple GAG chains per scaffold 
and mimic PGs. Therefore, these scaffolds can be utilized to define the biological 
significance of GAG multivalency. Towards this goal, a library of cluster-xylosides 
was designed that can prime multiple GAG chains per scaffold and mimic naturally 
occurring PGs. A library of mono-xylosides synthesized by “click chemistry” has been 
found to be stable under in vitro conditions and furthermore possesses good GAG 
priming activity (16). Therefore, mono-xylosides, bis-xylosides, and tris-xylosides, 
were synthesized, as shown in Table 5.1. Tetrakis-xylosides were received from Prof. 
Loganathan (IIT Madras, India). Fully acetylated xylosyl azide was conjugated to 
various hydrophobic molecules containing triple bonds by click chemical methodology 
and the resulting library of xylosides was deprotected under Zemplen condition to 
obtain the final products, as outlined in Scheme 5.1. The overall reaction yields of this 
two-step process, click chemistry and deprotection, range from 50% to 70%.
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Table 5.1. Structures of cluster-xylosides
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n= 1, 2, 3
Scheme 5.1. Synthesis of cluster-xylosides. a: acetone, deionized water, copper (II) 
sulfate, and sodium ascorbate. b: methanol and sodium methoxide
The final products 1-18 were purified on a reverse phase C18 column using HPLC as 
described in the “Experimental Methods” section [5.5] followed by structural analysis 
using NMR spectroscopy and mass spectrometry.
5.2.2. Priming Activity of Cluster-xylosides
A mutant CHO cell line, pgsA-745, is a convenient cellular system for 
determining the priming activity of cluster-xylosides because this cell line lacks an 
active xylosyltransferase enzyme and therefore does not make endogenous GAG chains. 
Thus, it is straightforward to determine the priming activity of cluster-xylosides using 
this cell line. The cluster-xylosides were screened at two concentrations, 100 ^M and 1 
mM. The primed GAGs were purified using mini DEAE-sepharose columns. It is 
interesting to note that deprotected bis-xylosides were able to prime at these 
concentrations with a tendency to prime better at the higher concentration. However, 
deprotected tris- and tetrakis-xylosides were unable to prime at both the concentrations, 
suggesting that these highly water soluble, polar molecular scaffolds experience 
difficulties in crossing the intracellular and/or outer membranes. For these reasons, 
fully acetylated tris- and tetrakis-xylosides were studied for their priming activity. 
Fully protected xylosides, 8-11, precipitated at 1 mM concentration in the cell culture
medium whereas these scaffolds were found to prime GAG chains without getting 
precipitated at the 100 |iM concentration in the cell culture medium. However, tris- and 
tetrakis-xylosides, 8-11 did not prime a significant amount of GAG chains.
Next, the effect of spacer length between xylose units was examined on the 
priming activity. The obtained data show that the distance between the xylose units 
located on a single scaffold affects the priming activity at 1 0 0  ^M concentration, as 
shown in Figure 5.2. At the 100 ^M concentration, as the spacer distance increases, the 
priming activity tends to decrease for all cluster-xylosides, suggesting that longer alkyl 
linkers may prohibit effective transport of cluster-xylosides across the membrane. At 1 
mM concentration, however, the spacer distance between the two xylose units did not 
have any effect on the priming activity of bis-xyloside due to overloading the bis- 
xyloside into cells.
5.2.3. Structural Analysis of Primed GAG Chains
In order to verify the multidirectional priming ability of cluster-xylosides, we 
analyzed the molecular weights of GAG chains induced by cluster-xylosides in pgsA- 
745 cells using size exclusion chromatography. The chain length of the GAG chains 
was determined by measuring the migration time of GAG chains in comparison to that 
of polystyrene sulfonate standards under similar conditions. The average molecular 
weights were found to be 16 kDa for GAG chains primed by mono-xyloside 1, 55 kDa 
for GAG chains primed by bis-xyloside 3, 32 kDa for GAG chains primed by tris- 
xyloside 8 , and 40 kDa for GAG chains primed by tetrakis-xyloside 10. The tris- 
xyloside produced GAG chains with a higher average molecular weight than the mono- 
xylosides but lower molecular weight than the bis-xylosides, possibly due to
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Figure 5.2. Prim ing activity of cluster-xylosides. CHO cells were treated with 
cluster- xylosides at 100 |iM in the presence of 3H-GlcNH2 (100 |iCi) as described in 
the “Experimental Methods” section [5.5]. The GAG chains were purified by anion 
exchange chromatography and quantitated using a liquid scintillation counter. A: 
Priming activity of bis-xylosides, B: Priming activity of tris-xylosides and C: Priming 
activity of tetrakis-xylosides. The results were the average of two independent 
experiments that were carried out in duplicate.
molecular steric hindrance that decreased enzyme efficiency during GAG biosynthesis 
(Figure 5.3). Therefore, the structures of induced GAG chains were analyzed by bis- 
xylosides in pgsA-745 cells in detail. Though these xylosides prime better at 1 mM 
concentration compared to 100 ^M concentration, the primed GAG chains have 
significantly lower molecular weights (Figure 5.4A). It is possible that at such a high 
concentration, the GAG biosynthetic machinery is overloaded and unable to produce 
large GAG chains. Interestingly, the spacer distance between the two residues in bis-
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Figure 5.3. Molecular weight profiles of GAG chains primed by cluster-xylosides.
GAG chains primed by cluster-xylosides at 100 |iM concentration in pgsA-745 cells for 
24 h. The purified GAG chains were analyzed by size exclusion chromatography, 
fractionated on two tandem 3000 SWXL columns, and were eluted with an isocratic 
gradient of phosphate buffer for 90 minutes at a flow rate of 0.5 ml/ min as described in 
the experimental section. A: The elution profiles of GAG chains primed by mono- 
xyloside 1 (gray trace, control) and bis-xyloside 3 (black trace). B: The elution profiles 
of GAG chains primed by mono-xyloside 1 (gray trace, control) and tris-xyloside 8 
(black trace). C: The elution profiles of GAG chains primed by mono-xyloside 1 (gray 
trace, control) and tetrakis-xyloside 10 (black trace).
xylosides did not affect the average MWs of primed GAG chains even though the 
spacer distance affected their priming activity at 1 0 0  ^M concentration.
To analyze the sulfation patterns of primed GAGS, we utilized high-pressure 
DEAE anion-exchange chromatography. The sulfate density of GAG chains primed by 
bis-xylosides was largely unaffected by alkyl linkers. Notably, GAG chains primed at 
lower concentrations contained more sulfate groups than GAGs primed at higher 
concentrations. Additionally, the sulfation pattern of GAGs primed at 100 ^M was less 
polydisperse and more homogenous than at the 1 mM concentration (Figure 5.4B). The 
HS/CS composition of primed GAG chains was determined by treating them with 
heparitinases I/II/III. It was found that these bis-xylosides in this study prime CS 
predominantly and relatively smaller quantities of HS (see the “Supporting 
Information” [5.6]). Earlier studies, including our own, have shown that aglycone 
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Figure 5.4. Structural analysis of primed GAG chains. A. Size exclusion profiles of 
GAG chains primed by bis-xyloside 3 at 100 |iM and 1 mM concentrations in pgsA-745 
cells for 24 h. The primed GAG chains were analyzed by size exclusion 
chromatography and were eluted with an isocratic gradient of phosphate buffer for 90 
minutes at a flow rate of 0.5 ml/ min as described in the “Experimental Method” section 
[5.5]. The elution profiles of bis-xyloside 3 at 1 mM (gray trace) and at 100 |iM (black 
trace). B. Sulfate density profile of GAG chains primed by bis-xyloside 3 in pgsA-745 
cell lines at 1 mM (gray trace) and at 100 |iM (black trace) were analyzed using anion 
exchange HPLC: the bound GAG chains were eluted with a linear gradient of 0.2 M to 
1 M NaCl over 80 minutes at a flow rate of 1 ml/min. These elution profiles are 
representative of two independent experiments.
naphthyl or aryl group tend to prime more HS chains. For these reasons, additional bis- 
xyloside scaffolds were synthesized in which phenyl- or naphthyl- group containing 
linkers were used to bridge two xylose residues, as shown in Table 5.2.
In our later efforts, we primarily focused on synthesizing additional bis- 
xylosides only as they tend to prime GAG chains with higher molecular weights and 
less polydispersity than tris- and tetrakis- xylosides. The additional scaffolds, 12-17, 
primed mostly CS chains and very few HS chains, even though they carry phenyl or
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naphthyl groups. Nevertheless, bis-xylosides should mimic PGs such as biglycan that 
carry two CS chains and therefore can be used as potential PG mimetics to define the 
GAG multivalency in the biological systems. Furthermore, it is possible that these 
scaffolds prime different GAG types in other cellular systems.
To determine the disaccharide composition, the purified GAG chains were 
digested with chondroitinase ABC, which digests CS chains into disaccharides. The 
radiolabeled disaccharides were then identified by comparison of their elution positions 
relative to those of disaccharide standards. Disaccharide analysis revealed that primed 
CS chains composed of two major disaccharides, AUA-GalNAc and AUA-GalNAc(4S). 
GAG chains primed by the bis-xylosides, at 100 ^M concentration, were composed 
mostly of 4-O-sulfated disaccharide (Figure 5.5).
Figure 5.5. Disaccharide profiles of bis-xyloside primed CS chains. GAG chains, 
which were primed by bis-xylosides 3 at 100 |iM and 1 mM, were treated with 
chondroitinase ABC. The enzyme treated GAG chains were analyzed using SAX- 
HPLC with inline flow scintillation analyzer along with CS disaccharide standards 
“AUA-GalNAc, AUA-GalNAc2S, AUA-GalNAc4S, AUA-GalNAc6 S.” The resulting 
disaccharides were “I: AUA-GalNAc; and II: AUA-GalNAc4S.”
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5.2.4. Evidence of Bidirectional Priming by Bis-xylosides
In order to verify bidirectional priming by bis-xyloside, the primed GAG chains 
by mono-xylosides and bis-xylosides were cleaved by periodate oxidation-alkaline 
elimination. GAG chains primed by mono-xylosides was not cleaved under periodate 
oxidation-alkaline elimination condition (Figure 5.6A) but GAG chains primed by bis- 
xylosides were cleaved from 55 kDa to 20 kDa (Figure 5.6B). It suggested that bis- 
xylosides primed bidirectional GAG chains, which mimic the natural PGs. 
Bidirectional priming by bis-xylosides was verified again by ozonolysis reaction. GAG 
chains that were primed by bis-xyloside 18, containing a double bond, cleaved 
selectively under an ozone condition. (see “Supporting Information” [5.6]).
Figure 5.6. Periodate oxidation-alkaline elimination of GAG chains. GAG chains, 
which were primed by mono-xyloside 2 and bis-xyloside 7 at 100 |iM, were subjected 
to periodate oxidation-alkaline elimination. A: The elution profiles of GAG chains 
primed by mono-xyloside 2  (gray trace) and periodate oxidation-alkaline elimination of 
GAG chains primed by mono-xyloside 2 (black trace). B: The elution profiles of GAG 
chains primed by bis-xyloside 7 (gray trace) and periodate oxidation-alkaline 
elimination of GAG chains primed by bis-xyloside 7 (black trace).
5.3. Discussion
A distinct structural feature of all PGs, with the exception of decorin, is that the 
core protein is substituted with two or more GAG chains. In addition, PGs exhibit a 
molecular polymorphism attributed to differences in their GAG chain valency and size 
(7). The multivalent nature of PGs has been suggested to be important in regulating a 
wide variety of cellular processes, including optimal function of syndecans in cell 
invasion, migration, and adhesion (20). A recent study has exemplified the cooperative 
interaction of fibroblast growth factor (FGF) 2 with heparin oligosaccharides attached 
to the dendrimer in potentiating FGF2 activity (21).
Click-xylosides carrying different aglycone moiety were demonstrated that 
prime diverse GAG chains and suggested the presence of GAGOSOMEs that can 
regulate the production of cell-specific combinatorial GAG structures with distinct 
sulfation pattern, size, and type (17, 22-24). In this report, we examined a method to 
assess the effect of the distance between two GAG initiation sites on priming activity, 
the type of GAG produced, GAG sulfate density and chain length. Available data 
suggest that bis-xylosides prime GAG chains that have higher molecular weights and 
less polydispersity in comparison to those that are primed by tris- or tetrakis-xylosides. 
Although bis-xylosides prime better at 1 mM concentration compare to 100 ^M 
concentration, primed GAG chains are lower in their molecular weights. This could be 
due to the overloading of GAG biosynthetic machinery with xylosides. We have also 
found that the spacer distance between the two residues in bis-xylosides did not affect 
average MWs of primed GAG chains even though the spacer distance affected their 
priming activity at 1 0 0  ^M concentration.
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Cluster-xylosides primed mostly CS chains and very few HS chains, even 
though they carry phenyl or naphthyl groups. Nevertheless, bis-xylosides should mimic 
PGs such as biglycan that carry two CS chains and therefore can be used as potential 
PG mimetics to define the GAG multivalency in the biological systems. Furthermore, it 
is possible that these scaffolds prime different GAG types in other cellular systems 
(Figure 5.7).
Lander et al. proposed a two-step biosynthetic model in which the decisions to 
attach CS or HS to a core protein are made sequentially (25). If this were true, one 
would expect to observe distinct GAG types at two different GAG initiation sites that 
are in close proximity within the same scaffold. It is therefore tempting to propose an 
alternative model in which scaffolds reach specific GAGOSOMEs through their 
selective trafficking into the Golgi where they are committed for assembling either HS 
or CS/DS at multiple initiation sites as long as the initiation sites are in close proximity. 
However, the model proposed by Lander may very well be true if there are additional 
unknown factors that can recognize protein sequences and thereby facilitate the 
assembly mechanism in a two-step process that eventually leads to the production of 
PGs carrying both HS and CS/DS on the same core protein. Thus, the biosynthetic 
machinery cannot impose these molecular restrictions on cluster-xylosides as these 
scaffolds lack such elaborative structural features to facilitate the two-step process.
5.4. Conclusions
In summary, a wide variety of cluster-xylosides carrying single, two, three, or 
four xylose residues per scaffold were synthesized using click chemistry and
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Figure 5.7. Structural analysis of GAG chains primed by bis-xyloside. PgsA-745 
cells were incubated with the bis-xyloside 3 at 100 |iM for 24 h. The HS/CS 
composition of the primed GAG chains was determined by digesting the GAG chains 
with heparitinase I/ II/ III and chondroitinase ABC enzymes. The reaction mixture was 
loaded on to two tandem G3000 SWXL columns (7.8 mm x 30 cm) and analyzed with 
the aid of an inline radiometric detector using phosphate buffer (100 mM KH2PO4, 100 
mM NaCl, pH 6 ) as an eluent. A: The elution profile of GAG chains without enzymes 
treatment. B: The elution profile of GAG chains with heparitinase I/ II/ III. C: The 
elution profile of GAG chains after treatment with chondroitinase ABC enzyme.
systematically studied for their ability to stimulate GAG biosynthesis. Cluster- 
xylosides primed multiple GAG chains per scaffold mimicking endogenous PGs. 
However, most of these cluster-xylosides primed predominantly CS chains and very 
few HS chains. Future studies will involve the synthesis of additional scaffolds to 
delineate the PG biosynthetic pathways, determine priming of HS chains, and examine 
the biological significance of GAG multivalency in a systematic manner.
5.5. Experimental Methods
Anhydrous solvents were purchased and used directly or dried over standard 
drying agents and freshly distilled prior to use. Reactions were monitored by TLC on 
silica gel 60 F-254 with detection by Von’s reagent. Intermediate compounds were 
purified by flash chromatography columns using silica gel 60 (230-400 mesh) and were 
run under medium pressure at 5-7 psi. Final products were purified by high 
performance liquid chromatography (HPLC) on a reverse phase C18 column (VYDAC
2.2 cm*25 cm) with solvent A (25 mM formic acid in water) and solvent B (95% 
acetonitrile) at a flow rate of 5 ml/min in a linear gradient over 120 minutes starting 
with 0% B. All synthetic compounds were characterized by NMR using a Varian 
Mercury 400 MHz spectrometer. The compounds were also confirmed for their final 
structures by electrospray inonization mass spectrometry (ESI-MS) using a Finnigan 
LCQ mass spectrometer or a Bruker Q-Tof mass spectrometer in either positive or 
negative ion mode .
The mutant Chinese hamster ovary (CHO) cell line, pgsA-745, was obtained 
from American Type Culture Collection. The cell culture reagents for the CHO cell 
line were obtained from HyClone. Tritium glucosamine (3H) and Ultima-FloAP flow 
scintillation mixture for flow radiometric analysis were obtained from Perkin Elmer 
Life Sciences. All other chemicals and biochemicals were obtained from Sigma 
Aldrich. DEAE-Sepharose gel was purchased from Amersham Biosciences. The 
anion-exchange column, TSKgel DEAE-3SW (7.4 mm x 7.5 cm), and the size 
exclusion column, G3000SWXL (7.8 mm x 30 cm), were obtained from Tosoh 
Bioscience. Anhydrous solvents were purchased and used directly or dried over 
standard drying agents and freshly distilled prior to use.
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5.5.1. Synthesis of Cluster-xylosides
Compound S2: 1, 3-Benzenedimethanol (3.618 mmol, 500 mg) was treated with 
31 % HBr in acetic acid (5 ml). The reaction was stirred at room temperature for 2 h. 
After addtion of dicholoromethane (10 ml), the organic solvent was washed with water, 
saturated bicarbonate solution, dried over Na2 SO4, and evaporated. The crude material 
was purified by flash chromatography on silica gel to give the compound (S2) (900mg, 
90% yield). 1H NMR (CDCfe): 5 7.42 (1H, s), 7.33 (3H, d, J  = 1.2 Hz), 4.48 (4H, s) 
(Scheme S5.1 and Table S5.1).
Compound S3: To an anhydrous THF solution (10 ml) of alcohol carrying an 
alkyne group (2 mmol) was added sodium hydride (3 mmol). The reaction mixture was 
stirred for 30 minutes at room temperature under argon atmosphere followed by the 
addition of (S2) (1 mmol). The mixture was stirred overnight at room temperature. 
THF solvent was evaporated. The crude material was dissolved in ethyl acetate, 
washed with water and then saturated sodium chloride solution, dried over Na2 SO4, and 
evaporated. The residue was purified by column chromatography to give the compound 
(S3) (Scheme S5.1 and Table S5.1).
Compound S3a: 1H NMR (CDCh) 5 7.34-7.25 (4H, m), 4.51 (4H, s), 3.58 (4H, 
t, J  = 6 . 6  Hz), 2.51 (4H,dt, J  = 6 .8 , 2.7 Hz), 2.00 (2H, t, J  = 2.7 Hz).
Compound S3b: 1H NMR (CDCh) 5 7.34-7.25 (4H, m), 4.51 (4H, s), 3.58 (4H, 






Scheme S5.1. Preparation of precursors carrying alkyne group for click chemistry 
Table S5.1. Yields of reactions
n S3 Yield (%)
2 S3a 84%
3 S3b 97%
Compound S5: To an anhydrous THF solution (10 ml) of compound (S4) (1 
mmol) was added sodium hydride ([m+1] mmol). The reaction mixture was stirred for 
30 minutes at room temperature under argon atmosphere followed by addition of 
propargyl bromide ([m+1] mmol). The mixture was stirred overnight at room 
temperature. Solvent was evaporated. The crude material was dissolved in ethyl 
acetate and washed with water and saturated sodium chloride solution, dried over 
Na2 SO4 and evaporated. The residue was purified by column chromatography to give 
the compound (S5) (Scheme S5.2 and Table S5.2).
Compound S5a: 1H NMR (CDCl3) 5 7.39-7.30 (4H, m), 4.61 (4H, s), 4.18 (4H, 
d, J  = 2.3 Hz), 2.47 (2H, t, J  = 2.3 Hz)
Compound S5b: 1H NMR (CDCl3) 5 7.35 (4H, s), 4.61 (4H, s), 4.17 (4H, d, J  =
2.3 Hz), 2.45 (2H, t, J  = 2.3 Hz)
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Scheme S5.2. Preparation of propargylated precursors for the synthesis of bis­
and tris-xylosides
Table S5.2. Yields of reactions
S4 m S5 Yield (%) Reference*
HO' OH S5a 48% N/A
HO A




* the procedure was slightly modified rom the published reports
Compound S5c: 1H NMR (CDCl3) 5 4.12 (4H, d, J  = 2.4 Hz), 3.61-3.58 (12H, 
m), 2.38 (2H, s)
Compound S5d: 1H NMR (CDCfe) 5 4.12 (6 H, d, J  = 2.4 Hz), 3.51 (6 H, t, J  = 
5.9 Hz), 2.42 (3H, t, J  = 2.4 Hz), 2.03-1.99 (6 H, m), 1.55-1.48 (6 H, m)
Compound S7: To the solution (10 ml) of compound (S6 ) (1 mmol) in acetone, 
was added potassium carbonate (3 mmol). The reaction mixture was stirred for 30 






mixture was stirred overnight. The reaction mixture was concentrated. The resulting 
crude material was dissolved in ethyl acetate, washed with water and saturated sodium 
chloride solution, dried over Na2 SO4, and rotary evaporated under reduced pressure. 
The residue was purified by column chromatography to give the compound (S7) 
(Scheme S5.3 and Table S5.3).
Compound S7a: 1H NMR (CDCfe) 5 7.89 (2H, d, J  = 7.8), 7.38 (2H, t, J  = 7.8), 
6.97 (2H, d, J  = 7.0), 4.88 (4H, s), 2.53 (2H, s)
Compound S7b: 1H NMR (CDCfe) 5 7.68 (2H, d, J  = 8 . 6  Hz), 7.19 (4H, d, J  = 
12.1 Hz), 4.78 (4H, s), 2.54 (2H, s).
Compound S8 : Nitromethanetrispropanol (2.127 mmol) was dissolved in SOCl2 
(42.54 mmol). The reaction mixture was refluxed at 60 °C. After the completion of 
reaction, the reaction mixture was dissolved in ethyl acetate and washed with water, 
brine, and then dried over Na2 SO4. The final mass is 380 mg (62 %) and the crude 
product was used in the next step without any further purification (Scheme S5.4).. 1H 




Scheme S5.3. Preparation of additional propargylated precursors
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Table S5.3. Yields of reactions
S6 S7 Yield (%) Reference
H Oop
O H
S7a 2 0 % (28)
HOxaOH S7b 56% (29)
* The procedures were modified from the published reports
Compound S9: The compound (S8 ) (1.275 mmol) was dissolved in dry 
DMF (10 ml) followed by addition of sodium azide (6.38 mmol). The reaction was 
heated to 90 °C under stirring. After completion of the reaction as indicated by TLC, 
the reaction mixture was dissolved in ethyl acetate, washed with water and brine, and 
then dried over Na2SO4 (Scheme S5.4). The final mass is (270mg, 6 6 %). 1H NMR 
(CDCl3): 5 3.28 (2H, t, J  = 6 . 6  Hz), 1.95-1.91 (2H, m), 1.47-1.39 (2H, m).
Compound S11: To a solution of alkyne (S5c) (4.98 mmol) and xylosyl azide 
(S10) (1.66 mmol) in 8  ml of acetone and water (1:1) solvent mixture, sodium ascorbate 
(0.66 mmol) was added, followed by Cu2 SO4. 5H20 (1.33 mmol) at room temperature, 
and the mixture was stirred until disappearance of compound (S10) (as indicated by 
TLC). At the end of the reaction, the reaction mixture was evaporated using rotary 
evaporator under reduced pressure to obtain the final product (360 mg, 41%) (Scheme 
S5.5).(30, 31) 1H NMR (CD3OD): 5 8.24 (1H, s), 6.02 (1H, d, J  = 8 . 6  Hz), 5.58-5.47 
(2H, m), 5.23-5.17 (1H, m), 4.64 (2H, s), 4.25 (1H, dd, J  = 5.9, 11.3 Hz), 4.18 (2H, d, J  
= 2.3 Hz), 3.77 (1H, t, J  = 10.9 Hz), 3.66-3.62 (12H, m), 2.83 (1H, t, J  = 2.3 Hz), 2.04 
(3H, s), 2.02 (3H, s), 1.83 (3H, s)
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Scheme S5.4. Preparation of the precursor for the synthesis of tris-xyloside 9
Scheme S5.5. Synthesis of mono-xylosides using click chemistry
To a solution of propargylated precursors (1 mmol) and xylosyl azide (1, 2 or 3 
mmol for the synthesis of mono-, bis- or tris-xylosides, respectively) in acetone ( 8  ml) 
and water (2 . 6  ml) mixture, excess sodium ascorbate was added, followed by 
CuSO4 .5H2O (0.4 mmol) at room temperature and the mixture was stirred until the 
disappearance of the starting materials, as indicated by TLC. At the end of the reaction, 
the reaction mixture was concentrated using a rotary evaporator under reduced pressure 
and the syrup obtained was dissolved in ethyl acetate and washed with water. Finally, 
the organic layers were washed with saturated sodium chloride and the crude products 
were purified by silica flash column to give the desired protected xylosides. 
Deprotection procedure: Fully acetylated xyloside ( 1  mmol) was taken in dry methanol 
( 1 0  ml) and treated with freshly prepared 1 M solution of sodium methoxide in dry 
methanol until the solution reaches pH ~9, as indicated by pH paper. After the 
deacetylation was complete, as indicated by TLC, H+ resins were added to bring the pH 
to 7. The reaction mixture was then filtered, concentrated under reduced pressure to the 
crude product, and was further purified on HPLC-reverse phase C18 column with
solvent A (25 mM formic acid in water) and solvent B (95% acetonitrile) to give the 
deprotected-xylosides (1-9 and 12-18) (Scheme S5.6).
Xyloside 1: 1H NMR (CD3OD): 5 7.98 (1H, s, triazolyl H), 5.47 (1H, d, J  = 9.4 
Hz, H-1), 4.00 (1H, dd, J  = 5.1, 11.3 Hz, H-5a), 3.87 (1H, t, J  = 9.4 Hz, H-2), 3.67-3.63 
(1H, m, H-4), 3.49 (1H, t, J  = 9.0 Hz, H-3), 3.45 (1H, t, J  = 10.9 Hz, H-5b), 2.92 (2H, t, 
J  = 7.4 Hz,), 2.54 (2H, dt, J  = 2.3 Hz, 7.4 Hz), 2.27 (1H, t, J  = 2.7 Hz); 13C NMR 
(CD3OD): 5 147.4, 122.7, 90.2, 83.8, 78.6, 73.9, 70.7, 70.5, 69.8, 25.9, 19.3; ESI-MS: 
Calcd for Cn H 15N 3O4Na: 276.0960 [M+Na]+, Found 275.9333.
Xyloside 2: 1H NMR (CD3OD): 5 7.89 (1H, s, triazolyl H), 5.45 (1H, d, J  = 9.4 
Hz, H-1), 4.00 (1H, dd, J  = 5.1, 11.1 Hz, H-5a), 3.87 (1H, t, J  = 9.4 Hz, H-2), 3.69-3.63 
(1H, m, H-4), 3.48 (1H, t, J  = 9.4 Hz, H-3), 3.45 (1H, t, J  = 10.9 Hz, H-5b), 2.71 (2H, t, 
J =  7.8 Hz,), 2.17-2.14 (3H, m), 1.72-1.65 (2H, m), 1.52-1.36 (6 H, m); 13C NMR 
(CD3OD): 5 149.2, 122.2, 90.1, 85.0, 78.7, 73.8, 70.7, 69.8, 69.5, 30.4, 29.7, 29.6, 29.5,
26.2, 19.0; ESI-MS: Calcd for C30H46N 6O8Na: 641.3275 [2M+Na]+, Found 640.7333.
Xyloside 3: 1H NMR (CD3OD): 5 7.84 (2H, s, triazolyl H), 5.45 (2H, d, J  = 9.4 
Hz, H-1), 3.99 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.83 (2H, t, J  = 9.4 Hz, H-2), 3.69-3.63 
(2H, m, H-4), 3.48 (2H, t, J  = 9.0 Hz, H-3), 3.44 (2H, t, J  = 10.9 Hz, H-5b), 3.09 (4H, 
s); 13C NMR (CD3OD): 5 169.0, 122.7, 90.2, 78.6, 74.0, 70.7, 69.8, 26.2; ESI-MS: 















-O  ,n ~N 
SOH
n= 1, 2, 3 (Table 1 & 2)
Scheme S5.6. Synthesis of cluster-xylosides using click chemistry(30, 31)
Xyloside 4: 1H NMR (CD3OD): 5 7.94 (2H, s, triazolyl H), 5.46 (2H, d, J  = 9.4 
Hz, H-1), 3.99 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.87(2H, t, J  = 9.4 Hz, H-2), 3.70-3.64 
(2H, m, H-4), 3.49 (2H, t, J  = 9.0 Hz, H-3), 3.45 (2H, t, J  = 10.9 Hz, H-5b), 2.76 (4H, t, 
J  = 7.4 Hz), 2.05 (2H, p, J  = 7.4 Hz); 13C NMR (CD3OD): 5 148.4, 122.5, 90.2, 78.6, 
73.9, 70.7, 69.8, 29.9, 25.5; ESI-MS: Calcd for C 17H27N 6O8: 443.1890 [M+H]+, Found 
442.8667.
Xyloside 5: 1H NMR (CD3OD): 5 7.89 (2H, s, triazolyl H), 5.45 (2H, d, J  = 9.4 
Hz, H-1), 3.99 (2H, dd, J  = 5.1, 11.1 Hz, H-5a), 3.86 (2H, t, J  = 9.4 Hz, H-2), 3.69-3.63 
(2H, m, H-4), 3.48 (2H, t, J  = 9.0 Hz, H-3), 3.45 (2H, t, J  = 11.3 Hz, H-5b), 2.74 (4H, t, 
J  = 6 . 6  Hz), 1.75-1.72 (4H, m); 13C NMR (CD3OD): 5 148.9, 122.3, 90.2, 78.7, 73.9,
70.7, 69.8, 29.7, 25.9; ESI-MS: Calcd for C 18H29N 6O8 : 457.2047 [M+H]+, Found 
456.9333.
Xyloside 6 : 1H NMR (CD3OD): 5 7.89 (2H, s, triazolyl H), 5.46 (2H, d, J  = 9.4 
Hz, H-1), 4.00 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.87(2H, t, J  = 9.4 Hz, H-2), 3.70-3.64 
(2H, m, H-4), 3.49 (2H, t, J  = 9.0 Hz, H-3), 3.45 (2H, t, J  = 11.3 Hz, H-5b), 2.71 (4H, t, 
J  = 7.8 Hz), 1.75-1.68 (4H, m), 1.42 (2H, p, J  = 7.8 Hz); 13C NMR (CD3OD): 5 149.1,
122.3, 90.1, 78.7, 73.9, 70.7, 69.8, 30.0, 29.5, 26.1; ESI-MS: Calcd for C 19H31N 6O8 : 
471.2203[M+H]+, Found 471.0000.
Xyloside 7: 1H NMR (CD3OD): 5 7.89 (2H, s, triazolyl H), 5.45 (2H, d, J  = 9.4 
Hz, H-1), 3.99 (2H, dd, J  = 5.1, 11.3 Hz, H-5a), 3.87 (2H, t, J  = 9.0 Hz, H-2), 3.70-3.63 
(2H, m, H-4), 3.48 (2H, t, J  = 9.0 Hz, H-3), 3.45 (2H, t, J  = 11.3 Hz, H-5b), 2.69 (4H, t, 
J  = 7.4 Hz), 1.70-1.66 (4H, m), 1.41-1.38 (4H, m); 13C NMR (CD3OD): 5 149.2, 122.3,
90.1, 78.7, 73.9, 70.7, 69.8, 30.2, 29.8, 26.1; ESI-MS: Calcd for C20H32N A N a : 
507.2179 [M+Na]+, Found 507.1333.
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Xyloside 8: 1H NMR (CDCfe): 5 7.78 (3H, s, triazolyl H), 5.80 (3H, d, J  = 9.0 
Hz, H-1), 5.44-5.38 (6H, m, H-2, H-3), 5.20-5.14 (3H, m, H-4), 4.59 (6H, s), 4.29 (3H, 
dd, J  = 5.5, 11.5 Hz, H5-a), 3.60 ( 3H, t, J  = 11.3 Hz, H-5b ); 3.45 ( 6H, t, J  = 5.9 Hz), 
2.07 ( 9H, s, Ac-H), 2.05 ( 9H, s, Ac-H), 1.98-1.94 (6H, m), 1.86 ( 9H, s, Ac-H), 1.51­
1.44 (6H, m); ESI-MS: Calcd for C53Hy6N wO26Na: 1275.4517 [M+Na]+, Found 
1275.2039.
Xyloside 9: 1H NMR (MeOD): 5 8.23 (3H, s, triazolyl H), 7.97 (3H, s, triazolyl 
H), 6.02 (3H, d, J  = 9.0 Hz, H-1), 5.57 (3H, t, J  = 9.4 Hz, H-2 ), 5.49 (3H, t, J  = 9.4 Hz, 
H-3), 5.23-5.163 (3H, m, H-4), 4.64 (6H, s), 4.62 (6H, s), 4.37 (6H, t, J  = 6.6 Hz), 4.23 
(3H, dd, J  = 5.5 Hz, 11.5 Hz, H-5a), 3.76 (3H, t, J  = 10.9 Hz, H-5b), 3.64-3.59 (36H, 
m), 2.04 (9H, s, Ac-H), 2.01 (9H, s, Ac-H), 1.89-1.84 (6H, m), 1.82 (9H, s, Ac-H), 1.65 
(6H, m); 3C NMR (CD3OD): 5 171.5, 171.5, 170.5, 146.7, 125.4, 124.2, 94.4, 87.2,
73.8, 72.0, 71.5, 71.5, 70.8, 70.7, 69.8, 66.2, 65.0, 64.8, 50.7, 33.0, 25.4, 20.6, 20.6,
20.2. ESI-MS: Calcd for C79H UyN19O35Na: 1914.7857 [M+Na]+, Found 1914.4667.
Xyloside 12: 1H NMR (CD3OD): 5 8.16 (2H, s, triazolyl H), 7.37 (1H, s, Ar-H), 
7.33-7.28 (3H, m, Ar-H), 5.52 (2H, d, J  = 9.4 Hz, H-1), 4.65 (4H, s), 4.58 (4H, s), 
4.01(2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.90 (2H, t, J  = 9.0 Hz, H-2), 3.709-3.647 (2H, m, 
H-4), 3.50 (2H, t, J  = 9.4 Hz, H-3), 3.47 (2H, t, J  = 10.9 Hz, H-5b; 13C NMR (CD3OD):
144.8, 138.3, 128.4, 127.4, 127.3, 123.1, 89.0, 77.4, 72.7, 72.0, 69.5, 68.7, 62.8; ESI- 
MS: Calcd for C24H33N 6O 10: 565.2258 [M+H]+, found 565.1189.
Xyloside 13: 1H NMR (CD3OD): 5 8.14 (2H, s, triazolyl H), 7.34 (4H, s), 5.51 
(2, d, J  = 9.4 Hz, H-1), 4.65 (4H, s), 4.58 (4H, s), 4.01 (2H, dd, J  = 5.1, 11.1 Hz, H-5a), 
3.88 (2H, t, J  = 9.4 Hz, H-2), 3.71-3.64 (2H, m, H-4), 3.49 (2H, t, J  = 9.4 Hz, H-3), 3.46
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(2H, t, J  = 10.9 Hz, H-5b); ESI-MS: Calcd for C ^ ^ O ^ N a :  587.2078 [M+Na]+, 
found 587.2000.
Xyloside 14:1H NMR (CD3OD): 5 7.91 (2H, s, triazolyl H), 7.22 (1H,s , Ar-H), 
7.21 (2H, d, J  = 7.0 Hz, Ar-H), 7.29 ( 1H, t, J  = 7.0 Hz, Ar-H), 5.46 (2H, d, J  = 9.0 Hz, 
H-1), 4.51 (4H, s), 3.99 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.86 (2H, t, J  = 9.0 Hz, H-2), 
3.74 (4H, t, J  = 6 . 6  Hz), 3.67-3.63 (2H, m), 3.49 (2H, t, J  = 9.0 Hz, H-3), 3.45 ( 4H, t, J  
= 10.9 Hz, H-5b), 3.00 (4H, t, J  = 6 . 6  Hz,); ESI-MS: Calcd for C ^ ^ ^ O ^ N a :  
615.2391 [M+Na]+, found 615.1550.
Xyloside 15: 1H NMR (CD3OD): 5 7.83 (2H, s, triazolyl H), 7.34-7.25 (4H, m),
5.44 (2H, d, J  = 9.0 Hz, H-1), 4.51 (4H, s), 3.99 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.83 
(2H, t, J  = 9.0 Hz, H-2), 3.70-3.64 (2H, m), 3.54-3.42 (8 H, m), 2.81 (4H, t, J  = 7.8 Hz),
1.99-1.92 (4H, m); ESI-MS: Calcd for C ^ ^ ^ O ^ N a :  643.2704 [M+Na]+, found 
643.2667.
Xyloside 16: 1H NMR (CD3OD): 5 8.33 (2H, s, triazolyl H), 7.81 (2H, d, J  = 8 . 6  
Hz, Ar-H), 7.35 (2H, t, J  = 7.8 Hz, Ar-H), 7.10 (2H, d, J  = 7.8 Hz, Ar-H), 5.55 (2H, d, J  
= 9.0 Hz, H-1), 5.35 (4H, s), 4.02 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.93 (2H, t, J  = 9.0 
Hz, H-2), 3.74-3.65 (2H, m, H-4), 3.50 (2H, t, J  = 9.0 Hz, H-3), 3.48 (2H, t, J  = 11.3 
Hz, H-5b); 13C NMR (CD3OD): 5 155.2, 145.1, 128.1, 126.3, 124.6, 115.9, 107.2, 90.3,
78.6, 73.9, 70.7, 69.9, 62.7; ESI-MS: Calcd for C ^ H ^ O ^ :  585.1945 [M-H]', found 
585.0000.
Xyloside 17: 1H NMR (CD3OD): 5 8.32 (2H, s, triazolyl H), 7.73 (2H, d, J  = 9.0 
Hz, Ar-H), 7.39 (2H, s, Ar-H), 7.18 (2H, d, J  = 9.0 Hz, Ar-H), 5.55 (2H, d, J  = 9.0 Hz, 
H-1), 5.29 (4H, s), 4.01 (2H, dd, J  = 5.5, 11.3 Hz, H-5a), 3.91 (2H, t, J  = 9.4 Hz, H-2), 
3.70-3.64 (2H, m, H-4), 3.49 (2H, t, J  = 9.4 Hz, H-3), 3.48 (2H, t, J  = 10.94 Hz, H-5b);
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13C NMR (CD3OD): 5 156.4, 145.1, 131.4, 129.6, 124.7, 120.2, 108.6, 90.2, 78.7, 73.9,
70.7, 69.9, 62.4; ESI-MS: Calcd for C26H29N 6O 10: 585.1945 [M-H]-, found 585.0667.
Xyloside 18: 1H NMR (CD3OD): 5 8.22 (2H, s, triazolyl H), 5.73 (2H, s), 5.55 
(2H, d, J  = 9.4 Hz, H-1), 4.60 (4H, s), 4.12 (4H, s), 4.01 (2H, dd, J  = 5.5, 11.3 Hz, H- 
5a), 3.91 (2H, t, J  = 9.4 Hz, H-2), 3.67-3.53 (2H, m, H-4), 3.51-3.44 (4H, m, H-3, H- 
5b); Calcd C2cH3cN6O 1cNa: 537.202 [M+Na]+, found 537.151
5.5.2. Screening of Cluster-xylosides in CHO Cells
To determine whether cluster-xylosides were able to prime GAG chains, the 
cells were treated with cluster-xylosides at 100 |iM or 1 mM concentration in the 
presence of 3H-glucosamine. Primed GAGs were purified and analyzed as described 
below. 4x105 cells were seeded per well in complete growth medium in a 6 -well plate. 
The cells were incubated at 37 °C in a humidified incubator for 24 h to 50% confluency. 
The cells were then washed with sterile PBS and replaced with 990 |iL DMEM 
containing 10% dialyzed FBS and 1mM of glucose. A solution containing a specific 
primer at 100x the final concentration was prepared. 10 |iL of appropriate 100X primer 
stock were added to various wells to achieve an appropriate concentration. 1 0 0  |iCi of 
3H-glucosamine was also added to each well as tracer. The 6 -well plates were 
incubated at 37 °C in a humidified incubator (5% CO2) for 24 h.
5.5.3.Purification and Quantitation of GAG Chains
The entire content of each well was transferred to a microcentrifuge tube and 
subjected to centrifugation at 16000xg- for 5 minutes. The supernatant was transferred 
to a fresh tube and 0.016% Triton X-100 (1.5 volumes) was added. The diluted
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supernatant was loaded on 0.2 ml DEAE-sepharose column pre-equilibrated with 2ml of 
wash buffer (20mM NaOAc, 0.1 M NaCl and 0.01% Triton X-100, pH 6.0) and the 
column was washed with 6  ml of wash buffer. The bound HS/CS was eluted with 1.2 
ml of elution buffer (20mM NaOAc and 1M NaCl, pH 6.0). The priming activity of 
cluster-xylosides was evaluated by measuring the 3H-radioactivity incorporated into the 
purified GAG chains using liquid scintillation counter.
5.5.4. Analysis of Primed GAG Chains
Anion-exchange HPLC analysis: The purified GAG chains were analyzed by 
HPLC with an inline radiometric detector. Xyloside primed GAG chains of equal 
quantity were diluted five-fold with HPLC solvent A (10 mM KH2PO4, pH 6.0, 0.2% 
CHAPS) for anion-exchange chromatography analysis. The sample was loaded on a 
HPLC-DEAE column and eluted from the column with a linear gradient of 0.2 M - 1 M 
NaCl over 80 minutes at a flow rate of 1ml/min. The radiolabeled GAG chains were 
detected by a radiometric flo-one A505A detector. The HPLC effluent was mixed with 
Ultima-Flo AP scintillation cocktail at 1:2 ratio and detected in the flow scintillation 
analyzer.
Size exclusion HPLC analysis: The chain length of the GAG chains synthesized 
by various cluster-xylosides was determined by measuring the migration time on two 
tandem G3000SWXL (Tosoh, 7.8 mm x 30 cm) size exclusion columns using the 
HPLC Hitachi system with an inline radiodetector. The solvent containing phosphate 
(100 mM KH2PO4, 100 mM NaCl, pH 6 ) was used as an eluent. The average molecular 
weight was determined by measuring the migration time of GAG chains in comparison 
to those of polystyrene sulfonate standards examined under similar conditions.
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Compositional analysis: The HS/CS composition of the primed GAG chains was 
determined by digesting the GAG chains with heparitinase I/II/III or chondroitinase 
ABC enzymes. The solution containing GAGs was diluted to 0.2 M NaCl, followed by 
the addition of heparitinase or chondroitinase ABC buffer and 5 mU of heparitinase 
I/II/III or chondroitinase ABC enzyme. The reaction mixture was incubated at 37 °C 
for 2 h, the solution was then loaded onto two tandem G3000 SWXL columns (7.8 mm 
x 30 cm) and analyzed with the aid of an inline radiometric detector using phosphate 
buffer (100 mM KH2PO4, 100 mM NaCl, pH 6 ) as an eluent. The percentage of HS/CS 
was determined based on the percentage area of undigested and digested GAG peaks.
Disaccharide analysis: the disaccharide composition of CS chains was 
determined by digesting the GAG chains with chondroitinase ABC enzymes. The 
enzyme treated GAG chains were loaded to SAX-HPLC with inline flow scintillation 
analyzer along with CS disaccharide standards “AUA-GalNAc, AUA-GalNAc2S, AUA- 
GalNAc4S, AUA-GalNAc6 S” . The sample was eluted from the column with a linear 
gradient of 0 M -  0.18 M NaCl over 100 minutes at a flow rate of 0.5 ml/min. The 
radiolabeled GAG chains were detected by a radiometric flo-one A505A detector. The 
HPLC effluent was mixed with Ultima-Flo AP scintillation cocktail at 1:2 ratio and 
detected in the flow scintillation analyzer.
Periodate oxidation-alkaline elimination reactions: Mono- and bis-primed GAG 
chains were subjected to periodate oxidation using 0.02 M NaIO4, 0.1 M sodium 
formate, pH 4.0 at 4 oC for 30 minutes. The reaction was stopped by addition of 0.04 M 
mannitol. The samples were desalted using 3000 cutoff membrane columns and 
subjected to alkali treatment with 0.1 M NaOH at pH 12 at 4 oC for 5 minutes (18).
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Ozonolysis of GAG chains: bis-xyloside 18 primed GAG chains were subjected 
to ozonolysis using ozone solution in dichloromethane. The reaction mixture was 
stirred for 30 minutes. The chain length of the GAG layer in water that was separated 
from the dichloromethane layer was determined by measuring the migration time on 
two tandem G3000SWXL (Tosoh, 7.8 mm x 30 cm) size exclusion columns using the 





Figure S5.1. Comparison of priming activity of mono-xylosides and bis-xylosides.
PgsA-745 cells were incubated with the mono-xylosides (1 and 2) and bis-xylosides (3,
4, 5, 6 and 7) at 100 |iMfor 24 h. The primed GAG chains were then purified and 














Figure S5.2. HS and CS compositions of GAG chains primed by bis-xyloside.
PgsA-745 cells were incubated with the bis-xyloside (3, 4, 5, 6 and 7) at 100 |iMfor 24 
h. The primed GAG chains were then purified as described in the experimental section. 
The HS/CS composition of the primed GAG chains was determined by digesting the 
GAG chains with heparitinase I, II, III and chondroitinase ABC enzymes. The reaction 
mixture was incubated at 37 °C for 2 h, the solution was then loaded onto two tandem 
G3000 SWXL columns (7.8 mm x 30 cm) and analyzed with the aid of an inline 
radiometric detector using phosphate buffer (100 mM KH2PO4, 100 mM NaCl, pH 6) as 
an eluent. The HS/CS composition was determined based on the percentage area of 
undigested and digested GAG peak.
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Figure S5.3. GAG priming activity was determined at 100 concentration by 
bis-xylosides. A: Priming activity of bis-xylosides (12 and 13). B: priming analysis of 
bis-xylosides (14, 15, 16 and 17). C: Priming activity of bis-xylosides (18 and 19). The 
priming ability of bis-xylosides were examined using xylosyl transferase deficient CHO 
cells (pgsA-745). 400,000 cells were seeded in wells of 6-well plates and treated with
bis-xylosides at 100 |iM in the presence of 100 |iCi of D-[6-3H]-glucosamine. The 
medium was removed from the well at 24 h, GAG chains were purified and quantified 
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Figure S5.4. Ozonolysis of GAG chains. GAG chains, which were primed by bis- 
xyloside 19 at 100 |iM, were subjected to ozonolysis reactions. A: two GAG chains per 
scaffold were primed by bis-xylosides 19 cleaved by ozone solution. B: The elution 
profiles of GAG chains primed by bis-xyloside 19 (black trace) and ozonolysis of GAG 
chains primed by bis-xyloside 19 (gray trace).
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Figure S5.6. Mass spectra of cluster-xyloside 1
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Figure S5.8. Mass spectra of cluster-xyloside 2
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Figure S5.10. Mass spectra of cluster-xyloside 3
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Figure S5.11. NMR spectra of cluster-xyloside 4
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Figure S5.12. Mass spectra of cluster-xyloside 4
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Figure S5.13. NMR spectra of cluster-xyloside 5
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Figure S5.16. Mass spectra of cluster-xyloside 6
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Figure S5.19. NMR spectra of cluster-xyloside 8
154
Time (min)
Sam ple_03 #8-29 RT: 0.35-1 20 AV: 11 NL: 5.23E7 












213.2315 279.2147 338.2610 405.1889 455.1299 517.1355 579.1105 625.4285
1275.2039 [M+Na]+
[M+H]+1253l635
I T -r-r 
250
825.1154 
713 5717 757.6332 |
300 850 
m lz




Figure S5.20. Mass spectra of cluster-xyloside 8
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Figure S5.21. NMR spectra of cluster-xyloside 9
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Figure S5.23. Mass spectra of cluster-xyloside 12
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Figure S5.26. Mass spectra of cluster-xyloside 14
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Figure S5.29. NMR spectra of cluster-xyloside 16
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Figure S5.30. NMR spectra of cluster-xyloside 17
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CHAPTER 6
CONCLUSIONS
GAGs play important roles in wound healing, cell signaling, cell proliferation, 
cell migration, cell differentiation, tumor metastasis, blood clotting, various infections, 
and numerous other biological processes (1-10). For example, HS and heparin contain a 
specific pentasaccharide sequence that binds with high affinity and activates anti­
thrombin III to inhibit blood clotting (11-13). However, direct administration of these 
animal derived heparins is wrought with problems of molecular heterogeneity, possible 
contamination with pathogens, and intentional chemical adulteration. Recently, an 
adulterated batch of heparin killed several hundred people in US, Germany, and other 
parts of the world (14). Moreover, the structure-function relationships of GAG chains are 
difficult to establish because of their structural complexity arising from their highly 
variable length and composition. An attractive alternative approach is to use xylosides to 
induce specific GAG chain biosynthesis without a core protein. Xylosides can act as 
acceptors for initiation of linkage region and production of GAG chains. It was 
demonstrated that the xylosides induced GAG chains secreted into the medium bearing 
the xyloside residues at the reducing end. In general, cells secrete PGs directly from 
Golgi into the extracellular environment by secretory pathway and some are shed from 
the cell surface through proteolytic cleavage of the core protein. Therefore, the primed 
GAG chains are also considered to be packaged in secretory vesicles in the Golgi 
apparatus and are secreted through exocytosis.
The quantity and type of GAG chains depends on the system where it was tested 
and also on the structure of aglycone moiety of xylosides. For example, P-xylosides 
produced low levels of CS in 1-day limb bub cells; however, they stimulated GAG 
biosynthesis 2 to 10 folds in glial cells, neuroblastoma, and two strains of hepatoma cells.
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Another example, P-D-xylosides carrying two aromatic rings efficiently primed more HS 
chains than P-D-xyloside carrying one aromatic ring.
The xylosides were also found to regulate many important biological processes 
such as the elongation of zebrafish embryos, angiogenesis, and invasion. The library of 
xylosides carrying various aglycone groups was synthesized using “click chemistry.” 
This approach introduces a diverse set of aglycones very quickly and allows one to 
examine the effect of aglycone moieties on the stimulation or inhibition of GAG chain 
biosynthesis in a variety of cellular systems rapidly. Moreover, these click-xylosides are 
stable up to 5 days in cells whereas traditional O-xylosides are hydrolytically unstable 
and degrade quickly within the cellular environment. Therefore, in this thesis, a library 
of click-xylosides was synthesized to address several questions related to GAG chain 
biosynthesis. In the future, these xylosides will be important tools to study structure- 
function relationship of GAG chains in vitro and in vivo and can potentially be used as 
drugs to treat cancers, cardiovascular diseases and CNS injury.
In the prior chapters, the extensive design and characterization of a number of 
xylosides that are important in studying the structures and functions of PGs have been 
shown. The primed chains are varied in terms of their sulfate density, average molecular 
weight, number of GAG chains per scaffold, and composition of GAG chains. The 
average molecular weight of primed GAG chains was calculated based on the migration 
time of polystyrene sulfonate standard. Then, this approach only provides apparent/ 
relative molecular weight rather than exact molecular weight since the structure of 
polystyrene sulfonate polymer is different from the structure of GAG chains. Therefore,
172
in the future, it is necessary to synthesize the GAG standard for determination of chain 
length of GAG chains.
6.1. Modulation of GAG Biosynthesis by Click-xylosides
Xylosides with hydrophobic aglycone groups can pass through cell membranes 
and compete with endogenous core protein acceptors for the assembly of GAG chains in 
the Golgi apparatus in vitro and in vivo. In our studies, the priming of these xylosides is 
concentration dependant and most of the xylosides generate a significant quantity of 
GAG chains at 100 |iM or higher concentrations. One possible explanation for this 
concentration dependence and the variety of priming activity is that the diffusion rates of 
the primers depend on the aglycones and lead to differential biosynthesis of the GAG 
chains. However, several xylosides primed more effectively at 100 |iM than at 1 mM. 
The inhibition of GAG priming at higher concentration of xylosides might be due to 
substrate level inhibition of the enzymes involved in assembly of the linkage region.
The aglycone group of xylosides affected not only the priming activity but also 
the sulfate density of primed GAG chains. Some xylosides produced homogeneously 
sulfated GAG chains, whereas other xylosides produced a heterogeneous population of 
variably sulfated GAG chains. The factors that regulate the appearance of cell-specific 
GAG chains with diverse sulfate patterns remain largely unknown. It has been proposed 
the GAG chains are synthesized in the Golgi by two different mechanisms (11, 15-17). 
In one mechanism, enzymes are anchored to the Golgi membrane at different locations 
and randomly modify and create diverse structures of GAG chains. In another 
mechanism, the diversity of GAG chains may be attributed to the presence of discrete
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enzyme complexes, named GAGOSOME, which are located in different Golgi sub­
compartments (11). Since a wide variation in the sulfate patterns of GAG chains primed 
by various xylosides were observed, these variations in the sulfate patterns should be 
attributed to the presence of discrete enzyme complexes in different Golgi compartments 
that may differentially regulate the biosynthesis of GAG chains. Selective 
compartmentalization of certain xylosides would likely result in the synthesis of 
homogenous and distinct populations of the GAG chains. However, other xylosides may 
be targeted to more than one GAGOSOME, resulting in the production of heterogenous 
GAG chains. Therefore, our study support the GAGOSOME mechanism that different 
xylosides can enter different GAGOSOME and that different GAGOSOME can make 
different GAG chains (15).
With regard to the chain composition, most xylosides that were studied made 
mostly CS. This observation supports the theory that the aglycone is not the only factor 
that affects the composition of GAG chains. Future studies will determine the effect of 
changing the glycosidic linkage of xylosides on the chain composition of GAGs 
produced. Utilizing xylosides with various types of glycosidic linkages may help 
elucidate the mechanism behind xyloside-stimulated GAG biosynthesis and may affect 
the percentage of HS chains in xyloside-stimulated GAGs.
Based on earlier studies, the aglycone group of xylosides is important in 
determining the amount of GAG produced and the specific structure of GAG chains 
produced. A library of 4-deoxy-4-fluoro-xylosides was designed based on the aglycones 
that primed effectively. These fluoro-xylosides were examined for their ability to inhibit 
endogenous GAG production. Surprisingly, a number of 4-deoxy-4-fluoro-xylosides
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selectively inhibited GAG biosynthesis without having any toxicity. Future studies will 
utilize the library to decipher the functions of HS and CS in vitro and in vivo by blocking 
the production of endogenous GAG chains.
6.2. Design of Fluorescent Xylosides to Profile Cell-specific GAG Chains
Deciphering dynamic changes in GAG structures will provide new avenues to 
diagnose disease states and to improve our understanding of the spatio-temporal roles of 
GAGs in development. Typically, radiolabels are utilized to track GAG chains in most 
cellular studies. However, these radiolabeled GAG chains are usually toxic for living 
organisms. Fluorescent xylosides may serve as excellent chemical probes to profile cell- 
specific GAG structures and to define the role of GAG chains in biological processes. 
Several groups have used the well-known scaffold, 4-methyl umbelliferyl-P-D-xyloside, 
for over 4 decades but it primes small CS chains and therefore has limited utility (18-20). 
To overcome this major impediment, novel fluorescent xylosides were designed and 
synthesized to prime larger GAG chains for potential use as chemical probes to 
understand GAG biosynthesis.
Pyrene xylosides and UMB-click-xylosides were able to prime GAG chains at 
various concentrations. The average MW of GAG chains induced by these fluorescent 
xylosides was much larger than the average MW of GAG chains induced by commercial 
4-methyl umbelliferyl-P-D-xyloside. Therefore, these fluorescent xylosides will provide 
novel avenues to profile and elucidate cellular GAG signatures in a robust manner, and 
assist in establishing cell-specific GAG-protein interactions. In future, additional 
fluorescent xylosides should be synthesized and screened for their ability to prime
specific HS or CS. These additional fluorescent xylosides will help to understand other 
factors that regulate the GAG biosynthesis and also be used to visualize Golgi 
compartments in order to prove the GAGOSOME concept.
6.3. RGD-xyloside Conjugates Prime GAGs
GAG chains play important roles in various cardiovascular functions and in 
various cancer processes (21-23). Heparin/HS activates ATIII, which eventually prevents 
the clot formation (24, 25). Moreover, HSPGs allow cancer cells to proliferate, escape 
from immune response and invade neighboring tissues (26, 27). RGD peptides can be 
targeted to activated endothelial cells and cancer cells which over express avp3integrins 
(28). Furthermore, RGD peptides can also prevent platelet aggregation by preventing 
binding of glycoprotein to the GPIIb/IIIa receptors (29). Given the important roles of 
GAG chains and RGD peptides in vascular and tumor biology, linear and cyclic RGD 
peptides were conjugated to xylose residues by utilizing “click chemistry.” These RGD- 
conjugated xylosides can be selectively targeted to activated endothelial cells and cancer 
cells. Our results have shown that linear-RGD conjugated xylosides were able to prime 
GAG chains in an endothelial cell and many cancer cells. However, cyclic RGD- 
conjugated xylosides were not able to prime GAG chains in endothelial cells or cancer 
cells. Many studies suggest that formation of HS on core proteins depends on the 
presence of hydrophobic amino acids next to xylosylation sites (30-32). For these 
reasons, in the future, a library of hydrophobically modified linear and cyclic RGD 
conjugated xylosides containing a hydrophobic amino acid including Ala, Leu, IIe, Phe, 
and Val should be designed to stimulate HS biosynthesis. Long-term future prospects for
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these molecules include their use in anticancer therapy and the treatment of myocardial 
infarcts as non-RGD-containing xylosides have been utilized to treat these diseases 
previously.
6.4. Synthesis and Biological Evaluation of Cluster-xylosides as PG Mimetics
Natural PGs normally contain more than two GAG side chains. In order to study 
the functions of PGs, cluster-xylosides carrying one, two, three, or four xylose residues 
per scaffold and various hydrophobic aglycones were synthesized using click chemistry. 
Based on the average MW analysis, “oxidation and elimination” reactions, and 
ozonolysis reactions, these synthetic cluster-xylosides induced multiple GAG chains per 
scaffold and mimicked naturally occurring PGs. Linker distances between xylose 
residues affected the priming activity but not the average MW of primed GAG chains. 
The average MW of GAG chains, however, was found to depend on the concentration of 
cluster-xylosides. The cluster-xylosides made significant CS/DS and less HS in CHO 
cells. Moreover, the effect of cluster-xylosides was also studied on zebrafish 
development. Only cluster-xylosides caused hyper-elongation of zebrafish embryos. It 
suggested that GAG multivalency in nature is important for their biological functions. 
Since these cluster-xylosides made significant quantities of CS and very few HS, future 
studies will examine the effect of different aglycone or glycosidic linkages on the amount 
of HS produced and the structure of primed GAGs (i.e. the effect of having one HS chain 
and one CS chain per scaffold).
In conclusion, understanding the structure-function relationship of GAGs will 
provide novel therapeutic targets to treat diseases such as cancers. However, the
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chemical heterogeneity and polydispersity of GAGs pose challenges for research and 
design of drugs. A library of xylosides, synthesized using click chemistry, has a potential 
to overcome this problem in the field since structures of PGs could be controlled by 
changing aglycones of xylosides. These stable click-xylosides stimulated various GAG 
structures. In the case of 4-fluoro-xylosides, they selectively inhibited PGs. In addition, 
these xylosides were easily conjugated to RGD peptides so that RGD-xylosides can 
function as blood thinner by priming anticoagulant GAG chains selectively at target sites 
such as activated endothelial cells and cancer cells. Cluster-xylosides primed multiple 
CS chains per scaffold and should be used as potential PG mimetics to define the GAG 
multivalency in the biological systems. In summary, click-xylosides will serve as a great 
tool to study the structure-function relationship of GAG chains in vitro and in vivo and 
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